<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐IL‐5 therapies for asthma - Farne, HA - 2022 | Cochrane Library</title> <meta content="Anti‐IL‐5 therapies for asthma - Farne, HA - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010834.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐IL‐5 therapies for asthma - Farne, HA - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010834.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010834.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐IL‐5 therapies for asthma" name="citation_title"/> <meta content="Hugo A Farne" name="citation_author"/> <meta content="Imperial College" name="citation_author_institution"/> <meta content="hugo.farne@gmail.com" name="citation_author_email"/> <meta content="Amanda Wilson" name="citation_author"/> <meta content="University of Technology Sydney" name="citation_author_institution"/> <meta content="Stephen Milan" name="citation_author"/> <meta content="Lancaster University" name="citation_author_institution"/> <meta content="Emma Banchoff" name="citation_author"/> <meta content="University of Michigan" name="citation_author_institution"/> <meta content="Freda Yang" name="citation_author"/> <meta content="Chelsea and Westminster Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Colin VE Powell" name="citation_author"/> <meta content="Sidra Medciine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD010834.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010834.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010834.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010834.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [therapeutic use]; Antibodies, Monoclonal [therapeutic use]; *Asthma [drug therapy]; Chronic Disease; Disease Progression; *Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010834.pub4&amp;doi=10.1002/14651858.CD010834.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010834\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010834\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010834.pub4",title:"Anti\\u2010IL\\u20105 therapies for asthma",firstPublishedDate:"Jul 12, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010834.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010834.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010834.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010834.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010834.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010834.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010834.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010834.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010834.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010834.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6751 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010834.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0110"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-sec-0104"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/appendices#CD010834-sec-0115"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/supinfo/CD010834StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/supinfo/CD010834StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐IL‐5 therapies for asthma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#CD010834-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Hugo A Farne</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#CD010834-cr-0005">Amanda Wilson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#CD010834-cr-0006">Stephen Milan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#CD010834-cr-0007">Emma Banchoff</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#CD010834-cr-0008">Freda Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information#CD010834-cr-0009">Colin VE Powell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information/en#CD010834-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010834.pub4">https://doi.org/10.1002/14651858.CD010834.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010834-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010834-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010834-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010834-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010834-abs-0009">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010834-abs-0001" lang="en"> <section id="CD010834-sec-0001"> <h3 class="title" id="CD010834-sec-0001">Background</h3> <p>This is the second update of previously published reviews in the Cochrane Library (2015, first update 2017). Interleukin‐5 (IL‐5) is the main cytokine involved in the proliferation, maturation, activation and survival of eosinophils, which cause airway inflammation and are a classic feature of asthma. Studies of monoclonal antibodies targeting IL‐5 or its receptor (IL‐5R) suggest they reduce asthma exacerbations, improve health‐related quality of life (HRQoL) and lung function in appropriately selected patients, justifying their inclusion in the latest guidelines. </p> </section> <section id="CD010834-sec-0002"> <h3 class="title" id="CD010834-sec-0002">Objectives</h3> <p>To compare the effects of therapies targeting IL‐5 signalling (anti‐IL‐5 or anti‐IL‐5Rα) with placebo on exacerbations, health‐related quality‐of‐life (HRQoL) measures and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments. </p> </section> <section id="CD010834-sec-0003"> <h3 class="title" id="CD010834-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and two trials registers, manufacturers' websites, and reference lists of included studies. The most recent search was 7 February 2022. </p> </section> <section id="CD010834-sec-0004"> <h3 class="title" id="CD010834-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing mepolizumab, reslizumab and benralizumab versus placebo in adults and children with asthma. </p> </section> <section id="CD010834-sec-0005"> <h3 class="title" id="CD010834-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and analysed outcomes using a random‐effects model. We used standard methods expected by Cochrane. </p> </section> <section id="CD010834-sec-0006"> <h3 class="title" id="CD010834-sec-0006">Main results</h3> <p>Seventeen studies on about 7600 participants met the inclusion criteria. Six used mepolizumab, five used reslizumab, and six used benralizumab. One study using benralizumab was terminated early due to sponsor decision and contributed no data. The studies were predominantly on people with severe eosinophilic asthma, which was similarly but variably defined. One was in children aged 6 to 17 years; nine others included children over 12 years but did not report results by age group separately. We deemed the overall risk of bias to be low, with all studies contributing data of robust methodology. We considered the certainty of the evidence for all comparisons to be high overall using the GRADE scheme, except for intravenous (IV) mepolizumab and subcutaneous (SC) reslizumab because these are not currently licensed delivery routes. </p> <p>The anti‐IL‐5 treatments assessed reduced rates of 'clinically significant' asthma exacerbation (defined by treatment with systemic corticosteroids for three days or more) by approximately half in participants with severe eosinophilic asthma on standard care (at least medium‐dose inhaled corticosteroids (ICS)) with poorly controlled disease (either two or more exacerbations in the preceding year or Asthma Control Questionnaire (ACQ) score of 1.5 or more), except for reslizumab SC. The rate ratios for these effects were 0.45 (95% confidence interval (CI) 0.36 to 0.55; high‐certainty evidence) for mepolizumab SC, 0.53 (95% CI 0.44 to 0.64; moderate‐certainty evidence) for mepolizumab IV, 0.43 (95% CI 0.33 to 0.55; high‐certainty evidence) for reslizumab IV, and 0.59 (95% CI 0.52 to 0.66; high‐certainty evidence) for benralizumab SC. Non‐eosinophilic participants treated with benralizumab also showed a significant reduction in exacerbation rates, an effect not seen with reslizumab IV, albeit in only one study. No data were available for non‐eosinophilic participants treated with mepolizumab. </p> <p>There were improvements in validated HRQoL scores with all anti‐IL‐5 agents in severe eosinophilic asthma. This met the minimum clinically important difference (MCID) for the broader St. George's Respiratory Questionnaire (SGRQ; 4‐point change) for benralizumab only, but the improvement in the ACQ and Asthma Quality of Life Questionnaire (AQLQ), which focus on asthma symptoms, fell short of the MCID (0.5 point change for both ACQ and AQLQ) for all of the interventions. The evidence for an improvement in HRQoL scores in non‐eosinophilic participants treated with benralizumab and reslizumab was weak, but the tests for subgroup difference were negative. </p> <p>All anti‐IL‐5 treatments produced small improvements in mean pre‐bronchodilator forced expiratory flow in one second (FEV<sub>1</sub>) of between 0.08 L and 0.15 L in eosinophilic participants, which may not be sufficient to be detected by patients. </p> <p>There were no excess serious adverse events with any anti‐IL‐5 treatment; in fact, there was a reduction in such events with benralizumab, likely arising from fewer asthma‐related hospital admissions. There was no difference compared to placebo in adverse events leading to discontinuation with mepolizumab or reslizumab, but significantly more discontinued benralizumab than placebo, although the absolute numbers were small (42/2026 (2.1%) benralizumab versus 11/1227 (0.9%) placebo). </p> <p>The implications for efficacy or adverse events are unclear.</p> </section> <section id="CD010834-sec-0007"> <h3 class="title" id="CD010834-sec-0007">Authors' conclusions</h3> <p>Overall this analysis supports the use of anti‐IL‐5 treatments as an adjunct to standard care in people with severe eosinophilic asthma and poor symptom control. These treatments roughly halve the rate of asthma exacerbations in this population. There is limited evidence for improved HRQoL scores and lung function, which may not meet clinically detectable levels. The studies did not report safety concerns for mepolizumab or reslizumab, or any excess serious adverse events with benralizumab, although there remains a question over adverse events significant enough to prompt discontinuation. </p> <p>Further research is needed on biomarkers for assessing treatment response, optimal duration and long‐term effects of treatment, risk of relapse on withdrawal, non‐eosinophilic patients, children (particularly under 12 years), comparing anti‐IL‐5 treatments to each other and, in patients meeting relevant eligibility criteria, to other biological (monoclonal antibody) therapies. For benralizumab, future studies should closely monitor rates of adverse events prompting discontinuation. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010834-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010834-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010834-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010834-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010834-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010834-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010834-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010834-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010834-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010834-abs-0002" lang="en"> <h3>Mepolizumab, reslizumab or benralizumab for people already taking inhaled steroids and long‐acting beta 2‐agonists for their asthma </h3> <p><b>Key messages</b> </p> <p>• The asthma medicines mepolizumab, reslizumab and benralizumab reduced asthma attacks in selected individuals with severe asthma (those with high numbers of an inflammatory cell called an eosinophil in their blood). </p> <p>• There were small improvements in quality of life questionnaire scores and breathing tests, but these may be too small to be detected by patients. </p> <p><b>Review question</b> </p> <p>We considered in this review whether taking the medicines mepolizumab, reslizumab or benralizumab in addition to standard treatment (such as inhaled steroids and combination inhalers) are better than a placebo (a dummy medicine) for people with asthma. </p> <p><b>Background</b> </p> <p>Asthma is an inflammatory lung condition characterised by the narrowing of the airways, breathlessness, a tight chest and reduced quality of life. It affects around 350 million people worldwide. Mepolizumab, reslizumab and benralizumab are 'anti‐IL‐5' treatments that may help to reduce asthma symptoms. </p> <p><b>Study characteristics</b> </p> <p>Seventeen studies compared mepolizumab, reslizumab or benralizumab to a placebo in about 7600 people with asthma, most with severe disease. We summarised the results as they related to the occurrence of asthma attacks requiring additional treatment, quality of life, breathing tests, effects on a blood biomarker (the numbers of a type of inflammatory cell called eosinophils), and unwanted effects. </p> <p><b>Key results</b> </p> <p>We found that participants with severe asthma, who had high numbers of eosinophils in their blood, benefited from taking mepolizumab, reslizumab or benralizumab through reduced asthma attacks. There were small improvements in quality of life and breathing tests, but these may be too small to be detected by patients. We agree with international guidelines that say that these medicines can be added to standard treatment for people with severe asthma. Further research is needed to clarify some aspects, such as how to assess treatment response and how long to give treatment for. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence included in this review is provided by very well‐designed studies. We are confident that participants in the studies were randomly placed into different treatment groups, that neither they nor the study team were aware of the treatment they were receiving, and that the small number who did not complete the study did not affect the findings. </p> <p>This plain language summary is up to date as of 7 February 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010834-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010834-sec-0110"></div> <h3 class="title" id="CD010834-sec-0111">Implications for practice</h3> <section id="CD010834-sec-0111"> <p>The studies that are currently available provide evidence to support the use of anti‐IL‐5 treatments in adults with severe eosinophilic asthma, which have been incorporated into national and international guidelines (e.g. Global Initiative for Asthma's 2021 clinical consensus statement, <a href="./references#CD010834-bbs2-0325" title="Global Initiative for Asthma (GINA). Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. www.ginasthma.org2021.">GINA 2021</a>). These treatments appear to roughly halve the rate of asthma exacerbations in this patient population, for whom exacerbations are particularly troublesome (<a href="./references#CD010834-bbs2-0318" title="CustovicA , JohnstonSL , PavordI , GagaM , FabbriL , BelEH , et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy2013;68(12):1520-31. [PMID: 24410781]">Custovic 2013</a>). Importantly, no concerns about safety were reported for mepolizumab or reslizumab, and there were no excess serious adverse events with benralizumab, although there was a small but significant incidence of adverse events prompting discontinuation of benralizumab. There is limited evidence for improvement in health‐related quality‐of‐life scores and lung function, which may not meet clinically detectable levels. </p> <p>Whilst the majority of studies included children over the age of 12 years, these did not provide sufficient data to reach a conclusion about efficacy and safety in this population. The initial findings of <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>, a study in those aged 6 to 17 years, only available in abstract form, suggest similar efficacy to adults but the full results are eagerly awaited. </p> </section> <h3 class="title" id="CD010834-sec-0112">Implications for research</h3> <section id="CD010834-sec-0112"> <p>Further research is needed to identify biomarkers for assessing treatment response, what the optimal duration of treatment is, the long‐term effects of treatment and risk of relapse on withdrawal, the impact of eosinophil‐depleting treatment on parasitic or helminth infections, and to clarify how best to define the people who will benefit from this treatment, considering the availability of tests (e.g. sputum cell differentials) and thresholds (for blood eosinophil counts). Research is also needed in people with non‐eosinophilic asthma and younger age groups, both under 12 years, in whom there has been only one incompletely published study, and 12 to 18 years old, for whom data have not been reported separately. </p> <p>With regard to benralizumab in particular, future studies and observational studies should closely monitor the incidence of adverse events leading to discontinuation. </p> <p>There will be some people who are eligible for more than one anti‐IL‐5 agent and potentially also treatment with anti‐immunoglobulin E (omalizumab) and the newer treatments, anti‐IL‐4 receptor α subunit (blocking IL‐4 and IL‐13 signalling; dupilumab), and anti‐thymic stromal lymphopoietin (TSLP; tezepelumab). At present there are no direct comparisons from head‐to‐head studies, leaving the clinician faced with such patients in an evidence‐free quandary. The variability in enrolment criteria present an obstacle to conducting a network meta‐analysis. High‐quality, head‐to‐head studies are required; one is indeed underway comparing omalizumab and mepolizumab (<a href="./references#CD010834-bbs2-0215" title="NCT03476109. Study of magnitude and prediction of response to omalizumab and mepolizumab in adult severe asthma (PREDICTUMAB) [Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: a pragmatic multicenter trial in Belgium]. clinicaltrials.gov/ct2/show/NCT03476109 (first received 23 March 2018). ">NCT03476109</a>), more will be needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010834-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010834-sec-0008"></div> <div class="table" id="CD010834-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mepolizumab subcutaneous (SC) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mepolizumab (SC) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> mepolizumab (SC)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mepolizumab (SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 1.48 events per participant per year<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.81 fewer events per participant per year (95% CI 0.66 fewer to 0.94 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.45 (0.36 to 0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: range 24‐ 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.15 events per patient per year<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.10 fewer events per participant per year (95% CI 0.05 fewer to 0.12 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.36 (0.20 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0‐6 (lower is better)<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −0.4 to −0.5 units<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the intervention group was 0.38 units fewer (0.50 fewer to 0.26 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (SGRQ)<br/>Scale from: 0‐100 (lower is better)<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −7.9 to −9.0 units<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 6.4 units fewer (8.9 fewer to 4.0 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 4 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub><br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.086 L (± 0.031 L) to 0.120 L (0.047 to 0.192 L)<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference from placebo was a further 0.09 L (0.05 L to 0.14 L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>65 per 1000 (44 to 96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio 0.68 (0.46 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(3 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.60<br/>(0.19 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MCID</b> : minimum clinically important difference; <b>SC</b> : subcutaneous; <b>SGRQ</b>: St. George's Respiratory Questionnaire </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rounded mean of the rate in the placebo group of the three studies: 1.21 and 1.74.<br/><sup>b</sup>Rounded mean of the rate in the placebo group of the two studies: 0.10 and 0.20.<br/><sup>c</sup>Mean change in placebo taken from <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> and <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>. <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> did not provide the mean change for each group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010834-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mepolizumab intravenous (IV) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mepolizumab (IV) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> mepolizumab (IV)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mepolizumab (IV)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 2.51 events per participant per year<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 1.18 fewer events per participant per year (1.41 fewer to 0.90 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.53<br/>(0.44 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.32 events per participant per year<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.15 fewer events per participant per year (0.22 fewer to 0.04 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.52<br/>(0.31 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>690<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.18 to 0.71 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 higher<br/>(−0.06 lower to 0.47 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0‐6 (lower is better)<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −0.59 to −0.50 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.11 lower<br/>(−0.32 lower to 0.09 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: range 32 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.060 L (± 0.038 L) to 0.086 L (± 0.031 L) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.08 L</p> <p>(0.02 L higher to 0.15 L higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>690<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>99 per 1000 (62 to 157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio 0.59 (0.37 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>751<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(5 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.72<br/>(0.18 to 2.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV <sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous; <b>MCID</b> : minimum clinically significant difference; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rounded mean of the rate in the placebo group of the three studies: 1.74, 2.40 and 3.4.<br/><sup>b</sup>Rounded mean of the rate in the placebo group of the two studies: 0.20 and 0.43. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010834-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Reslizumab intravenous (IV) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Reslizumab (IV) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> reslizumab (IV)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with reslizumab (IV)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 1.54 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.93 fewer events per participant per year (1.09 fewer to 0.73 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.43<br/>(0.33 to 0.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.12 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.04 fewer events per participant per year (0.07 fewer to 0.02 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.67<br/>(0.39 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.779 to 0.89 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.28 higher<br/>(0.17 higher to 0.39 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1164<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0 to 6 (lower is better)<br/>Follow‐up: range 16 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −0.368 to −0.80 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.25 lower<br/>(−0.33 lower to −0.17 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1652<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.002 L (± 0.1216 L) to 0.215 (± 0.0484 L) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 L higher<br/>(0.07 L higher to 0.15 L higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1652<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/>(51 to 102) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.79<br/>(0.56 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1656<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(25 to 59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.66<br/>(0.43 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1659<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous <b>MCID</b> : minimum clinically significant difference; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010834-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Reslizumab subcutaneous (SC) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Reslizumab (SC) compared with placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> reslizumab (SC) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk for placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with reslizumab (SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.79 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.2 fewer events per participant per year (0.38 fewer to 0.06 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio</p> <p>0.79 (0.56 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.05 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.003 fewer events per participant per year (0.03 fewer to 0.05 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.94 (0.43 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was 1.06</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>0.08 higher (‐0.11 to 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0 to 6 (lower is better)<br/>Follow up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was ‐1.14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>‐0.09 lower (‐0.27 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (SGRQ)<br/>Scale from: 0 to 100 (lower is better)<br/>Follow up: 32 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was ‐13.1 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.3 lower (‐6.02 to ‐0.58 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 4 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was 0.23 L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>0.14 higher (0.06 to 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 4 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000 (41 to 151)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio</p> <p>0.97 (0.53 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 per 1000 (2 to 166)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio 4.87 (0.57 to 41.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MCID</b> : minimum clinically important difference; <b>SC</b> : subcutaneous; <b>SGRQ</b>: St. George's Respiratory Questionnaire </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded because of imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010834-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benralizumab subcutaneous (SC) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benralizumab (SC) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> benralizumab (SC)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with benralizumab (SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 1.2 events per participant per year<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.49 fewer events per participant per year (0.58 fewer to 0.41 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.59<br/>(0.52 to 0.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3112</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: range 48‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.11 events per participant per year<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.04 fewer events per participant per year (0.06 fewer to 0.002 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.68<br/>(0.47 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is greater heterogeneity (I² = 43%) owing to inclusion of participants with less severe asthma in <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> (a larger proportion who had only suffered 1 exacerbation the previous year, with correspondingly less potential for exacerbation) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: range 48‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.98 to 1.31 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 higher<br/>(0.11 higher to 0.35 higher)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1541<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0‐6 (lower is better)<br/>Follow up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −1.19 to −0.76 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.26 lower<br/>(‐0.34 lower to ‐0.17 lower)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2791</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from ‐0.01 L to 0.239 L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 L higher<br/>(0.08 L higher to 0.15 L higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2786</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>Follow‐up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/>(81 to 121) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.76 (0.62 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3304<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 48‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/>(9 to 36 ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio</p> <p>2.04 (1.03 to 4.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3253<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous; <b>MCID</b> : minimum clinically significant difference; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rounded mean of the rate in the placebo group of the eosinophilic and non‐eosinophilic arms (as applicable) or the three studies: 1.33, 1.21, 0.68, 0.49, 0.93, 1.21.<br/><sup>b</sup>Rounded mean of the rate in the placebo group of the two studies: 0.18 and 0.04.<br/><sup>c</sup>One point deducted to reflect the level of heterogeneity on this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010834-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010834-sec-0009"></div> <p>This is the second update of previously published reviews in the Cochrane Library (2015, updated 2017), evaluating the effects of therapies targeting IL‐5 signalling (anti‐IL‐5 or anti‐IL‐5Rα) with placebo on asthma. </p> <section id="CD010834-sec-0010"> <h3 class="title" id="CD010834-sec-0010">Description of the condition</h3> <p>Asthma is a chronic inflammatory condition affecting the airways in the lungs. It is characterised by symptoms of breathlessness, chest tightness, wheeze, and cough. These symptoms are due to variable airflow obstruction secondary to bronchial hyperresponsiveness and airway inflammation. These symptoms are variably and intermittently present in the natural course of the disease, with periods of acutely increased symptomatology called exacerbations. </p> <p>An estimated 350 million people worldwide currently suffer from asthma, with numbers increasing (<a href="./references#CD010834-bbs2-0324" title="GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respiratory Medicine2017;5(9):691-706. [PMID: 28822787]">GBD Study 2017</a>). Asthma causes a significant degree of morbidity and mortality: every year in the UK alone there are an estimated 2.7 million GP consultations, 121,000 hospital attendances, 93,900 admissions, and over 1000 deaths (<a href="./references#CD010834-bbs2-0350" title="MukherjeeM , StoddartA , GuptaRP , NwaruBI , FarrA , HeavenM , et al. The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Medicine2016;14(1):113. [PMID: 27568881]">Mukherjee 2016</a>). The annual cost in the UK has been estimated at GBP 1.1 billion. Current treatments, such as inhaled corticosteroids (ICS) and bronchodilators are well established, yet despite these almost half of people living with asthma experience an exacerbation each year (<a href="./references#CD010834-bbs2-0358" title="PriceD , FletcherM , Van der MolenT . Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Primary Care Respiratory Medicine2014;24:14009. [PMID: 24921985]">Price 2014</a>). </p> <p>Asthma is now recognised as a heterogeneous disease comprised of a number of different clinical phenotypes and molecular endotypes, although the precise definition of these remains a work in progress (<a href="./references#CD010834-bbs2-0367" title="WenzelSE . Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine2012;18(5):716-25. [PMID: 22561835]">Wenzel 2012</a>). Atopic or allergic asthma is generally considered the most common phenotype, representing roughly half of all people with asthma (<a href="./references#CD010834-bbs2-0368" title="WoodruffPG , ModrekB , ChoyDF , JiaG , AbbasAR , EllwangerA , et al. T-helper type 2-driven inflammation defines major sub phenotypes of asthma. American Journal of Respiratory and Critical Care Medicine2009;180(5):388-95. [PMID: 19483109]">Woodruff 2009</a>). Atopic asthma is thought to be driven by an excess of 'type 2 inflammation': an elevated number of type 2 helper T (Th2) cells and the cytokines they secrete, interleukin 4 (IL‐4), IL‐5 and IL‐13. A separate pathophysiological mechanism, in which type 2 innate lymphoid cells (ILC2s) produce large amounts of IL‐5 and IL‐13 (and to a lesser degree, IL‐4) is hypothesised to be important in a subgroup of asthma sufferers with eosinophilia but no allergies (<a href="./references#CD010834-bbs2-0309" title="BrusselleGG , MaesT , BrackeKR . Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nature Medicine2013;19(8):977-9. [PMID: 23921745]">Brusselle 2013</a>). This group is particularly important because they have severe asthma that is largely resistant to ICS and so have a high burden of disease. </p> <p>The cytokines IL‐4, IL‐5 and IL‐13 produce many of the classic features of atopic asthma, for example, eosinophilia (IL‐5 controls the proliferation, survival and recruitment of eosinophils), raised immunoglobulin E (IgE) levels (the result of B cell class switching in response to IL‐4 and IL‐13), mucus hypersecretion and airway hyperresponsiveness, both a potential consequence of IL‐13 (<a href="./references#CD010834-bbs2-0316" title="ChungKF . Targeting the interleukin pathway in the treatment of asthma. Lancet2015;386(9998):1086-96. [PMID: 26383000]">Chung 2015</a>). Treatments targeting these so called 'type 2 cytokines' have subsequently been developed and investigated for their potential in treating asthma. </p> </section> <section id="CD010834-sec-0011"> <h3 class="title" id="CD010834-sec-0011">Description of the intervention</h3> <p>One of the core pathological features of asthma is eosinophilic infiltration of the bronchial mucosa and airways (<a href="./references#CD010834-bbs2-0338" title="KayAB . The early history of the eosinophil. Clinical and Experimental Allergy2015;45(3):575-82. [PMID: 25544991]">Kay 2015</a>). Pro‐inflammatory mediators secreted by eosinophils cause damage to the epithelium, initiating vasodilatation, smooth muscle contraction and increased mucous secretion, which in turn is associated with increased airway hyperresponsiveness, asthma symptoms and airway narrowing (<a href="./references#CD010834-bbs2-0344" title="LiuY , ZhangS , LiDW , Jiang S-J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One2013;8(3):e59872. [DOI: 10.1371/journal.pone.0059872]">Liu 2013</a>). Thus increased airway eosinophil counts, for example following reduction in the dose of maintenance ICS, cause increased symptoms and asthma exacerbations (<a href="./references#CD010834-bbs2-0333" title="JatakanonA , LimS , BarnesPJ . Changes in sputum eosinophils predict loss of asthma control. American Journal of Respiratory and Critical Care Medicine2000;161(1):64-72. [PMID: 10619799]">Jatakanon 2000</a>). </p> <p>The proliferation, maturation, activation, recruitment and survival of eosinophils is under the control of IL‐5 (<a href="./references#CD010834-bbs2-0347" title="LopezAF , BegleyCG , WilliamsonDJ , WarrenDJ , VadasMA , SandersonCJ . Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. Journal of Experimental Medicine1986;163(5):1085-99. [PMID: 3486243]">Lopez 1986</a>), with the IL‐5 receptor being selectively expressed on eosinophils and basophils. Elevated levels of IL‐5 mRNA are seen in the bronchial biopsies of people with asthma and correlate with disease severity (<a href="./references#CD010834-bbs2-0331" title="HumbertM , CorriganCJ , KimmittP , TillSJ , KayAB , DurhamSR . Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. American Journal of Respiratory and Critical Care Medicine1997;156(3 Pt 1):704-8. [PMID: 9309982]">Humbert 1997</a>). IL‐5 signalling is therefore an attractive target in asthma, and has yielded three monoclonal antibodies: mepolizumab (trade name Nucala; GlaxoSmithKline), reslizumab (trade names Cinqair or Cinqaero; Teva) and benralizumab (trade name Fasenra; MedImmune/AstraZeneca). Mepolizumab and reslizumab both target IL‐5, whereas benralizumab binds the alpha chain of the IL‐5 receptor (IL‐5Rα) found on eosinophils and basophils. </p> </section> <section id="CD010834-sec-0012"> <h3 class="title" id="CD010834-sec-0012">How the intervention might work</h3> <p>Mepolizumab and reslizumab bind IL‐5 and interfere with its ligation to the IL‐5 receptor on eosinophils and basophils. Both reduce eosinophil counts in sputum, a sample from the lower airways, and blood in a dose‐dependent manner (<a href="./references#CD010834-bbs2-0365" title="WangYH , LiuYJ . Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clinical and Experimental Allergy2009;39(6):798-806. [PMID: 19400908]">Wang 2009</a>). Benralizumab binds IL‐5Rα to inhibit its activation and induces eosinophil apoptosis by natural killer cells via antibody‐dependent cell‐mediated cytotoxicity (<a href="./references#CD010834-bbs2-0341" title="KolbeckR , KozhichA , KoikeM , PengL , AnderssonCK , DamschroderMM , et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. Journal of Allergy and Clinical Immunology2010;125(6):1344-1353.e2. [PMID: 20513525]">Kolbeck 2010</a>). Benralizumab has also been shown to reduce sputum and blood eosinophil counts (<a href="./references#CD010834-bbs2-0310" title="BusseWW , KatialR , GossageD , SariS , WangB , KolbeckR , et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. Journal of Allergy and Clinical Immunology2010;125(6):1237-1244.e2. [PMID: 20513521]">Busse 2010</a>). </p> <p>All three have marketing licences for use in people with 'eosinophilic' asthma (variably defined) and it is logical that these drugs would be most effective in this subgroup of patients. Anti‐IL‐5 therapies might also theoretically be effective in patients with more relaxed definitions of eosinophilia, or in those defined as 'non‐eosinophilic' based on their blood eosinophil count but who may have an isolated elevation of eosinophils in the airways (i.e. sputum eosinophilia) or have an eosinophilia that has been suppressed by ICS treatment, or both. </p> </section> <section id="CD010834-sec-0013"> <h3 class="title" id="CD010834-sec-0013">Why it is important to do this review</h3> <p>As anti‐IL‐5 therapies become incorporated into national and international guidelines (e.g. the Global Initiative for Asthma (GINA)'s 2021 clinical consensus statement; <a href="./references#CD010834-bbs2-0325" title="Global Initiative for Asthma (GINA). Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. www.ginasthma.org2021.">GINA 2021</a>), and clinical practice, it is important that the evidence is reviewed and made available in the Cochrane Library. The first Cochrane Review focused on mepolizumab, at the time the only anti‐IL‐5 agent licensed (<a href="./references#CD010834-bbs2-0374" title="PowellC , MilanSJ , DwanK , BaxL , WaltersN . Mepolizumab versus placebo for asthma. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834.pub2]">Powell 2015</a>)<i>.</i> Reslizumab and benralizumab were subsequently approved by the <a href="https://www.fda.gov/" target="_blank">US Food &amp; Drug Administration</a> and <a href="http://www.ema.europa.eu/ema/" target="_blank">European Medicines Agency</a>, so the scope of the updated review was broadened to consider all anti‐IL‐5 therapies (<a href="./references#CD010834-bbs2-0372" title="FarneHA , WilsonA , PowellC , BaxL , MilanSJ . Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834.pub3]">Farne 2017</a>). They are compared to each other rather than pooled as there are potentially important differences in dose, route of administration (subcutaneous versus intravenous), and in the case of benralizumab, a significant difference in the mechanism of action that uniquely induces eosinophil and basophil apoptosis, which could improve efficacy, but equally increase the incidence of adverse events. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010834-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010834-sec-0014"></div> <p>To compare the effects of therapies targeting IL‐5 signalling (anti IL‐5 or anti‐IL‐5Rα) with placebo on exacerbations, health‐related quality‐of‐life (HRQoL) measures, and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010834-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010834-sec-0015"></div> <section id="CD010834-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010834-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) reported as full text, published as abstracts only, and unpublished data. </p> </section> <section id="CD010834-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included both adults and children with a diagnosis of asthma. We focused on collating data from people who had been reported as having eosinophilic asthma to analyse these individuals as a subgroup. We examined individual articles in order to determine how this group should be defined. </p> <p>We excluded individuals with respiratory comorbidities such as cystic fibrosis, and current smokers. We included former smokers provided they had a smoking history of less than 10 pack years. </p> </section> <section id="CD010834-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared anti‐IL‐5 therapy with placebo, in addition to current standard care for asthma (ICS, with or without a second controller such as a long‐acting beta<sub>2</sub> agonist (LABA)), provided the treatment period was 16 weeks or longer. </p> <p>In the case of dose‐ranging studies, we included data only for participants on doses likely to be used clinically, specifically 75 mg intravenous (IV) or 100 mg subcutaneous (SC) injections of mepolizumab, 3 mg/kg IV or 110 mg reslizumab SC, and 20 to 30 mg benralizumab SC. These are the licensed doses except 75 mg IV mepolizumab (only licensed for SC administration), 110 mg reslizumab SC (only licensed for IV administration) and 20 mg SC benralizumab (30 mg is the licensed dose). However, for benralizumab, we included the 20 mg dose used in the three previous phase 2a dose‐ranging studies (<a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>). </p> <p>We planned to include the following co‐interventions provided they were not part of the randomised treatment: leukotriene antagonists (LTRA), inhaled bronchodilators (including LABA), inhaled and oral corticosteroids (ICS and OCS respectively), oral aminophyllines and macrolide antibiotics. We excluded studies that initiated a reduction in standard asthma management (e.g. oral corticosteroids) as part of the protocol, as we felt that they were too dissimilar for meaningful comparison. </p> </section> <section id="CD010834-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We referred to the joint American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on standardising endpoints for asthma clinical studies to identify appropriate outcome measures (<a href="./references#CD010834-bbs2-0360" title="ReddelHK , TaylorDR , BatemanED , BouletLP , BousheyHA , BusseWW , et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine2009;180(1):59-99. [DOI: 10.1164/rccm.200801-060ST] [PMID: 19535666]">Reddel 2009</a>). These recommend that clinical studies should assess outcomes relevant to both goals of asthma management: current control of asthma symptoms, and reduced risk of exacerbations and other adverse outcomes (e.g. accelerated lung function decline, treatment side effects). The joint ATS/ERS statement notes that exacerbation frequency, symptoms and lung function are often discordant, thus endpoints assessing each need to be considered. </p> <p>Exacerbations are responsible for most of the morbidity, mortality and healthcare costs related to asthma, and therefore considered the primary outcome measure. The ATS/ERS statement defines severe exacerbations as including either use of systemic corticosteroids for at least three days, or emergency department treatment or admission requiring systemic corticosteroids (definitions in terms of changes from baseline in lung function, symptoms, or short‐acting β2 agonist use are not validated). </p> <p>Lung function, specifically low pre‐bronchodilator forced expiratory flow in one second (FEV<sub>1</sub>), the most commonly reported lung function measure in clinical studies, is a strong independent predictor of asthma exacerbations (<a href="./references#CD010834-bbs2-0356" title="OsborneML , PedulaKL , O'HollarenM , EttingerKM , StiboltT , BuistAS , et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest2007;132(4):1151-61. [PMID: 17573515]">Osborne 2007</a>), and is objective and reproducible. However, lung function and symptoms correlate poorly over time in individual patients, so it is recommended that both are monitored. There is no gold standard score for assessing asthma symptoms, with several validated and regularly used including the Asthma Control Questionnaire (ACQ) (<a href="./references#CD010834-bbs2-0336" title="JuniperEF , O'ByrnePM , GuyattGH , FerriePJ , KingDR . Development and validation of a questionnaire to measure asthma control. European Respiratory Journal1999;14(4):902-7. [PMID: 10573240]">Juniper 1999</a>), Asthma Control Test (ACT) (<a href="./references#CD010834-bbs2-0352" title="NathanRA , SorknessCA , KosinskiM , SchatzM , LiJT , MarcusP , et al. Development of the asthma control test: a survey for assessing asthma control. Journal of Allergy and Clinical Immunology2004;113(1):59-65. [PMID: 14713908]">Nathan 2004</a>), Asthma Quality of Life Questionnaire (AQLQ; <a href="./references#CD010834-bbs2-0335" title="JuniperEF , GuyattGH , EpsteinRS , FerriePJ , JaeschkeR , HillerTK . Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax1992;47(2):76-83. [PMID: 1549827]">Juniper 1992</a>), and the St George's Respiratory Questionnaire (SGRQ; <a href="./references#CD010834-bbs2-0334" title="JonesPW , QuirkFH , BaveystockCM . The St George's Respiratory Questionnaire. Respiratory Medicine1991;85:25-31.">Jones 1991</a>). We considered any one of these an adequate measure of symptoms and health‐related quality of life (HRQoL). </p> <p>Identifying potential patient safety issues are a priority in the evaluation of new drugs. We consider the decision to discontinue study medication because of an adverse event to be a useful clinical marker of severity with real‐world applicability, and have included this alongside serious adverse events, which would likely outweigh any potential benefits of the intervention. </p> <p>Anti‐IL‐5 treatments should result in a reduction in eosinophils. Moreover, as discussed earlier, increased eosinophil counts are associated with symptoms and exacerbations (<a href="./references#CD010834-bbs2-0333" title="JatakanonA , LimS , BarnesPJ . Changes in sputum eosinophils predict loss of asthma control. American Journal of Respiratory and Critical Care Medicine2000;161(1):64-72. [PMID: 10619799]">Jatakanon 2000</a>). We have therefore included eosinophil counts in the peripheral blood as a secondary outcome, a measure that is readily available in hospitals and clinics. </p> <section id="CD010834-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010834-list-0001"> <li> <p>Clinically significant asthma exacerbation, defined by treatment with a course (three days or more) of systemic corticosteroids (with or without hospital admission) </p> </li> </ol> </p> </section> <section id="CD010834-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010834-list-0002"> <li> <p>Asthma exacerbation requiring emergency department treatment or admission</p> </li> <li> <p>HRQoL (as measured by a validated questionnaire e.g. ACQ, AQLQ, SGRQ)</p> </li> <li> <p>Measures of lung function (e.g. FEV<sub>1</sub>) </p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Clinically significant adverse events, defined as those prompting treatment discontinuation</p> </li> <li> <p>Blood eosinophil counts</p> </li> </ol> </p> <p>Reporting one or more of the outcomes listed here in the study was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD010834-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010834-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified studies from the following databases and trials registries:</p> <p> <ol id="CD010834-list-0003"> <li> <p>Cochrane Airways Register, through the Cochrane Register of Studies (CRS) all years to 7 February 2022; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 2) via the Cochrane Register of Studies, all years to 7 February 2022; </p> </li> <li> <p>MEDLINE Ovid SP 1946 to 7 February 2022;</p> </li> <li> <p>Embase Ovid SP 1974 to 7 February 2022;</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), all years to 7 February 2022; </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>), all years to 7 February 2022. </p> </li> </ol> </p> <p>Database search strategies are detailed in <a href="./appendices#CD010834-sec-0116">Appendix 1</a>. The search strategies were developed and executed by the Cochrane Airways Information Specialist in collaboration with the review authors. We searched all databases from their inception to the present and imposed no restriction on language of publication. The search was first conducted in November 2013 and was updated in November 2014, March 2017, September 2020, March 2021 and February 2022. </p> </section> <section id="CD010834-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for study information (clinical trials registers on the GlaxoSmithKline (manufacturer of mepolizumab) and AstraZeneca (benralizumab) websites; the Teva (reslizumab) website does not have a clinical trials register). </p> <p>We searched for errata and retractions relevant to the included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) on 27 September 2021. </p> </section> </section> <section id="CD010834-sec-0026"> <h3 class="title" id="CD010834-sec-0026">Data collection and analysis</h3> <section id="CD010834-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For this review update we used Cochrane’s Screen4Me workflow to help assess the search results. Screen4Me comprises three components: known assessments ‐ a service that matches records in the search results to records that have already been screened in Cochrane Crowd and have been labelled as 'RCT' or as 'Not an RCT'; the RCT classifier — a machine‐learning model that distinguishes RCTs from non‐RCTs (<a href="./references#CD010834-bbs2-0348" title="MarshallIJ , Noel-StorrAH , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomised controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9(4):602-14.">Marshall 2018</a>); and if appropriate, Cochrane Crowd ‐ Cochrane's citizen science platform where 'the crowd' help to identify and describe health evidence (<a href="./references#CD010834-bbs2-0355" title="Noel-StorrAH , DooleyG , AffengruberL , GartlehnerG . Citation screening using crowdsourcing and machine learning produced accurate results: evaluation of Cochrane's modified Screen4Me service. Journal of Clinical Epidemiology2020;130:23-31.">Noel‐Storr 2020</a>). </p> <p>Following this initial assessment, two review authors (HF, CP) independently screened titles and abstracts of all the potential studies identified in the search using <a href="./references#CD010834-bbs2-0317" title="Covidence. Version accessed prior to 7 June 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> software to select potentially relevant studies that met the inclusion criteria. The same two review authors (HF, CP) independently screened the full text of these studies to identify studies for inclusion and exclusion, and they recorded reasons for excluding the ineligible studies. Any disagreement was resolved through discussion or, if required, by consulting a third review author (SJM); however, this was not necessary. We identified and excluded duplicates and collated multiple reports of the same clinical study so that each clinical study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD010834-bbs2-0349" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097]">Moher 2009</a>), and a <a href="./references#CD010834-sec-0128" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD010834-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form to record study characteristics and outcome data that had been piloted on at least one study in the review. Two review authors (HF, AW for the 2017 review; EB, FY for the additional studies in the 2022 review) extracted the following study characteristics from the included studies. </p> <p> <ol id="CD010834-list-0004"> <li> <p>Methods: study design, total duration of study, details of any run‐in period, number of study centres and location, study setting, withdrawals and date of study </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria </p> </li> <li> <p>Interventions: intervention, comparator, concomitant medications and excluded medications</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported </p> </li> <li> <p>Notes: funding for study and notable conflicts of interest of study authors</p> </li> </ol> </p> <p>The same review authors independently extracted outcome data from included studies. We noted in the <a href="./references#CD010834-sec-0127" title="">Characteristics of included studies</a> if outcome data were not reported in a usable way. We planned to resolve disagreements by consensus or by involving a third author (SJM), but this was not necessary. We transferred the data into Review Manager 5 (RevMan 5; <a href="./references#CD010834-bbs2-0361" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. The data extracted were additionally checked by the Cochrane Airways' statistician for the 2017 review; this role was fulfilled by one of the authors of the 2022 review (EB). Another review author (SJM) spot‐checked study characteristics for accuracy against the study report. </p> </section> <section id="CD010834-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HF, AW for the 2017 review; EB, FY for the additional studies in the 2022 review) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010834-bbs2-0330" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We planned to resolve any disagreements by discussion or by involving another review author (SJM), but this was not necessary. We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD010834-list-0005"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear, and provided a quotation from the study report together with a justification for this judgement in the description of the study under <a href="./references#CD010834-bbs1-0001" title="">Included studies</a>. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for an unblinded outcome assessment, risk of bias for all‐cause mortality may be very different from that for a patient‐reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a study author, we noted this under the study description in <a href="./references#CD010834-bbs1-0001" title="">Included studies</a> . </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <p>We conducted the review according to this published protocol and have reported any deviations from it in <a href="#CD010834-sec-0125">Differences between protocol and review</a>. </p> </section> <section id="CD010834-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as rate ratios and risk ratios, and continuous data as mean differences or standardised mean differences, which are presented with 95% confidence intervals. We entered data presented on a scale with a consistent direction of effect. </p> <p>We have undertaken meta‐analyses only where this was meaningful (i.e. if the treatments, participants and underlying clinical question were sufficiently similar for pooling to make sense). </p> <p>Where multiple study arms were reported in a single study (<a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>), we only included the arms with doses likely to be used clinically, that is, 75 mg IV or 100 mg mepolizumab SC, 3 mg/kg IV or 110 mg reslizumab SC, 20 to 30 mg SC benralizumab. We considered four‐weekly and eight‐weekly dosing schedules to be equally clinically valid and therefore pooled these data (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>). Mepolizumab and reslizumab can be administered by different routes (IV or SC); for the purpose of this review we considered these separately. </p> <p>In future updates of this review, we will narratively describe skewed data reported as medians and interquartile ranges. Where multiple study arms are reported in a single study, we will include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta‐analysis, we will halve the control (placebo) group to avoid double‐counting. </p> </section> <section id="CD010834-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We did not identify any cross‐over studies or cluster‐randomised studies for inclusion in this version of the review. If cross‐over studies are identified in the future, we will seek data from a paired analysis from the study report or authors in order to appropriately include data in the review using the inverse variance method. If we identify cluster‐randomised studies in the future, then analyses will be at the level of the individual while allowing for the clustering in the data by using the intracluster correlation coefficient. If this is not reported in the study, then we will impute it from similar studies. </p> </section> <section id="CD010834-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when we identified a study only as an abstract). If this was not possible and we thought that the missing data would introduce serious bias, we planned to explore the impact of including such studies in the overall assessment of results by a sensitivity analysis<b>.</b> </p> </section> <section id="CD010834-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity between studies visually by inspection of the forest plots and using the Chi<sup>2</sup> test (a P value less than 0.10 was considered significant due to the low power of the test). We also calculated the I² statistic (<a href="./references#CD010834-bbs2-0329" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>); this describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). Values of I² statistic range from 0% to 100%, with 0% representing no heterogeneity and 100% representing considerable heterogeneity. </p> <p>For this review, we defined heterogeneity as reported using the I² statistic as follows (<a href="./references#CD010834-bbs2-0319" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). </p> <p> <ol id="CD010834-list-0006"> <li> <p>0% to 40%: heterogeneity might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ol> </p> </section> <section id="CD010834-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If we are able to pool more than 10 studies for future versions, we will create and examine a funnel plot to explore possible small study biases and publication bias. </p> </section> <section id="CD010834-sec-0035"> <h4 class="title">Data synthesis</h4> <p>In view of the considerable clinical heterogeneity between the included studies, we used a random‐effects model. </p> <p>We combined data on outcomes at 6 months and 12 months. We also described data for other time points, where they were reported. </p> </section> <section id="CD010834-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Provided we had included sufficient studies, we planned to carry out subgroup analyses according to: </p> <p> <ol id="CD010834-list-0007"> <li> <p>eosinophilic individuals versus non‐eosinophilic individuals (as eosinophilia may be a prescribing requirement e.g. <a href="./references#CD010834-bbs2-0353" title="National Institute for Health and Care Excellence (NICE). Mepolizumab for treating severe refractory eosinophilic asthma. www.nice.org.uk/guidance/ta431 (accessed prior to 20 July 2017).">NICE 2017</a>); and </p> </li> <li> <p>age (e.g. 0 to 5 years, 6 to 16 years, 17 years and older).</p> </li> </ol> </p> <p>Using the outcomes:</p> <p> <ol id="CD010834-list-0008"> <li> <p>clinically significant asthma exacerbations;</p> </li> <li> <p>HRQoL (as measured by a validated questionnaire); and</p> </li> <li> <p>measures of lung function (e.g. FEV<sub>1</sub>). </p> </li> </ol> </p> <p>We used the formal test for subgroup interactions in <a href="./references#CD010834-bbs2-0361" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>. </p> </section> <section id="CD010834-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses if we included sufficient studies: </p> <p> <ol id="CD010834-list-0009"> <li> <p>excluding studies with an overall high risk of bias;</p> </li> <li> <p>excluding cross‐over studies and cluster‐randomised studies.</p> </li> </ol> </p> </section> <section id="CD010834-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables using the following outcomes.</p> <p> <ol id="CD010834-list-0010"> <li> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids</p> </li> <li> <p>Rate of exacerbations requiring emergency department treatment or admission</p> </li> <li> <p>HRQoL (as measured by a validated questionnaire: e.g. ACQ, AQLA, SGRQ )</p> </li> <li> <p>Measures of lung function (e.g. FEV<sub>1</sub>) </p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Clinically significant adverse events leading to discontinuation</p> </li> </ol> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in chapter 8 (<a href="./references#CD010834-bbs2-0330" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>) and Chapter 14 (<a href="./references#CD010834-bbs2-0362" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using <a href="./references#CD010834-bbs2-0326" title="GRADEpro GDT. Version accessed before 8 June 2022. Hamilton (ON): McMaster university (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> software. We have justified all decisions to downgrade or upgrade the certainty of the evidence using footnotes, and we have made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010834-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010834-sec-0039"></div> <section id="CD010834-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD010834-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified 1461 records (<a href="#CD010834-fig-0001">Figure 1</a>) in updated database searches, after duplicates were removed and following initial assessment by Cochrane Screen4Me (<a href="./references#CD010834-bbs2-0355" title="Noel-StorrAH , DooleyG , AffengruberL , GartlehnerG . Citation screening using crowdsourcing and machine learning produced accurate results: evaluation of Cochrane's modified Screen4Me service. Journal of Clinical Epidemiology2020;130:23-31.">Noel‐Storr 2020</a>), for this review. The latest search was run on 7 February 2022. </p> <div class="figure" id="CD010834-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD010834-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>After removing additional duplicates, 1456 records remained.</p> <p>Seventeen studies from 72 records met our inclusion criteria (see <a href="./references#CD010834-sec-0127" title="">Characteristics of included studies</a>). </p> <p>There are no ongoing studies and no studies awaiting classification.</p> <p>We excluded 289 records for various reasons (see <a href="./references#CD010834-sec-0128" title="">Characteristics of excluded studies</a>). In particular, we excluded records relating to the <a href="./references#CD010834-bbs2-0026" title="BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneO , YanceySW , et al. Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study. European Respiratory Journal2014;44 Suppl 58:2907. [CENTRAL: 1053369] BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneON , YanceySW , et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine2014;371(13):1189-97. [CENTRAL: 1013105] [EMBASE: 25199060] [PMID: 25199060]NCT01691508. Mepolizumab steroid-sparing study in subjects with severe refractory asthma [MEA115575: a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma]. clinicaltrials.gov/ct2/show/NCT01691508 (first received 20 September 2012). 4900126000001341 SehmiR , SmithSG , KjarsgaardM , RadfordK , BouletLP , LemiereC , et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clinical and Experimental Allergy2015;46(6):793-802. [CENTRAL: 1129187] [PMID: 26685004]">Bel 2014</a>, <a href="./references#CD010834-bbs2-0182" title="AyarsAG , AltmanLC , Potter-PerigoS , RadfordK , WightTN , NairP . Sputum hyaluronan and versican in severe eosinophilic asthma. International Archives of Allergy and Immunology2013;161(1):65-73. 4900100000077338 AyarsAG , AltmanLC , Potter-PerigoS , WightTN , NairP . Sputum hyaluronan as a biomarker of airway remodeling in severe asthma. Journal of Allergy and Clinical Immunology2011;127(2 Suppl 1):AB8. 4900100000027030 NairP , KjarsgaardM , ArmstrongS , EfthimiadisA , O'ByrnePM , HargreaveFE . Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. Journal of Allergy and Clinical Immunology2010;126(2):404-6. [CENTRAL: 759797] [PMID: 20621343]NairP , PizzichiniM , KjarsgaardM , InmanM , EfthimiadisA , PizzichiniE , et al. Prednisone sparing effect of mepolizumab on eosinophilic bronchitis with or without asthma a randomized placebo controlled trial. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A568[#509]. 4900100000023006 NairP , PizzichiniMM , KjarsgaardM , InmanMD , EfthimiadisA , PizzichiniE , et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New England Journal of Medicine2009;360(10):985-93. 4900100000023472 NCT00292877. The prednisone-sparing effect of anti-IL-5 antibody (SB-240563). clinicaltrials.gov/ct2/show/NCT00292877 (first received 15 February 2006). 4900100000020456 ">Nair 2009</a> and <a href="./references#CD010834-bbs2-0184" title="NairP , WenzelS , RabeKF , BourdinA , LugogoNL , KunaP , et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. New England Journal of Medicine2017;376(25):2448-58. ">Nair 2017a</a> studies because their protocols included maintenance oral steroid dose reduction (as specified in <a href="#CD010834-sec-0019">Types of interventions</a>). </p> </section> <section id="CD010834-sec-0042"> <h4 class="title">Included studies</h4> <p><a href="#CD010834-tbl-0006">Table 1</a> compares the design, numbers, interventions and participant groups in the included studies. See <a href="./references#CD010834-sec-0127" title="">Characteristics of included studies</a> for details of each study. </p> <div class="table" id="CD010834-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons of study characteristics</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> <br/><b>(number of participants)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design, follow‐up (weeks)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline asthma severity</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (route)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary and secondary outcomes</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a> </p> <p>(468)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACQ‐6 score ≥ 1.5; ≥ 2 exacerbations in the last year requiring systemic corticosteroids; blood eosinophils ≥ 300 cells/μL; and FEV<sub>1</sub> bronchodilator reversibility of &lt; 12% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS for ≥ 3 months; + additional controller for ≥ 3 months; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 110 mg (SC) or placebo every 4 weeks for 52 weeks (last dose at 48 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0011"> <li> <p>Clinical asthma exacerbations during 52‐week treatment period</p> </li> <li> <p>Change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Change from baseline in ACQ‐6 at week 52</p> </li> <li> <p>Change from baseline in AQLQ+12 at week 52</p> </li> <li> <p>Change from baseline in SGRQ at week 32</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a> </p> <p>(315)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group, fixed‐dosage, multicentre phase 3 (16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 400 cells/μL during 2‐4‐week screening period; and ACQ‐7 score ≥ 1.5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS; maintenance OCS not allowed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 0.3 mg/kg or 3 mg/kg (IV) or placebo every 4 weeks for 4 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0012"> <li> <p>Pre‐bronchodilator FEV<sub>1</sub>, FVC, FEF<sub>25-75</sub> </p> </li> <li> <p>ACQ, ACQ‐6, ACQ‐5</p> </li> <li> <p>ASUI</p> </li> <li> <p>AQLQ</p> </li> <li> <p>Rescue inhaler use</p> </li> <li> <p>Blood eosinophil levels</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a> </p> <p>(1204)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, parallel‐group, placebo‐controlled multicentre (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at enrolment; and FEV<sub>1</sub> &lt; 80% (if 12‐17 years old, &lt; 90%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years) high‐dose (≥ 500 μg/d FP or equivalent) ICS/LABA for ≥ 12 months</p> <p>Children (12‐17 years) at least medium‐dose (≥ 250 μg/day FP or equivalent) ICS/LABA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo either every 4 weeks or every 4 weeks for the first 3 doses then every 8 weeks or placebo for 48 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0013"> <li> <p>Annual exacerbation rate</p> </li> <li> <p>Pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Total asthma symptom score</p> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Annual rate of exacerbations requiring ED visit or hospital admission</p> </li> <li> <p>Post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>AQLQ(S)+12 score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a> </p> <p>(489)</p> <p>and</p> <p><a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a> </p> <p>(464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 duplicate RCTs, double‐blind, placebo‐controlled, parallel‐group, multicentre, phase 3 (52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 400 cells/μL during 2‐4‐week screening period; and ACQ‐7 score ≥ 1.5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS (i.e. ≥ 440 μg/day FP or equivalent daily); ± additional controller or maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 3 mg/kg (IV) or matching placebo every 4 weeks for 13 doses (last dose week 48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0014"> <li> <p>Annual frequency of exacerbations</p> </li> <li> <p>Change in FEV<sub>1</sub> from baseline over 16 weeks </p> </li> <li> <p>ACQ‐7 score</p> </li> <li> <p>ASUI score</p> </li> <li> <p>Rescue use of SABA</p> </li> <li> <p>Blood eosinophil count</p> </li> <li> <p>‐ AQLQ total score at weeks 16, 32 and 52</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a> </p> <p>(606)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, placebo‐controlled, multicentre dose‐ranging (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐6 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at least twice during screening; and morning pre‐bronchodilator FEV<sub>1</sub> 40%‐90% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐ to high‐dose ICS in combination with LABA for ≥ 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 2 mg, 20 mg or 100 mg (SC) or placebo every 4 weeks for the first 3 doses, then every 8 weeks (total 7 doses) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0015"> <li> <p>Annual exacerbation rate</p> </li> <li> <p>Change from baseline in FEV<sub>1</sub> </p> </li> <li> <p>Mean ACQ‐6 score</p> </li> <li> <p>Overall symptom score</p> </li> <li> <p>Mean AQLQ score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> </p> <p>(551)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled (24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 150 cells/μL at screening or ≥ 300 cells/μL in previous 12 months; and ≥ 2 exacerbations in previous 12 months; and FEV<sub>1</sub> &lt; 80% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS for ≥ 12 months; + additional controller for ≥ 3 months; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 100 mg (SC) or placebo every 4 weeks for 24 weeks (last dose at 20 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0016"> <li> <p>SGRQ</p> </li> <li> <p>Mean change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Proportion of SGRQ total score responders at week 24</p> </li> <li> <p>Mean change from baseline in ACQ‐5</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a> </p> <p>(496)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, placebo‐controlled, multicentre phase 3 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACQ‐7 score ≥ 1.5 (no selection based on blood eosinophils)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS; maintenance OCS not allowed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 3 mg/kg (IV) or matching placebo every 4 weeks for 4 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0017"> <li> <p>Change in FEV<sub>1</sub> from baseline </p> </li> <li> <p>ACQ‐7 score</p> </li> <li> <p>Rescue (SABA) use within previous 3 days</p> </li> <li> <p>FVC</p> </li> <li> <p>Blood eosinophils</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> </p> <p>(1306)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, parallel‐group, placebo‐controlled multicentre (56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at enrolment; and FEV<sub>1</sub> &lt; 80% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐ (≥ 250 μg/d FP or equivalent) to high‐dose (≥ 500 μg/d FP or equivalent) ICS/LABA for ≥ 12 months; high‐dose ICS/LABA for ≥ 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo either every 4 weeks or every 4 weeks for the first 3 doses then every 8 weeks or placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0018"> <li> <p>Annual exacerbation rate for participants with blood eosinophils ≥ 300 cells/μL</p> </li> <li> <p>Pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Total asthma symptom score</p> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Annual rate of exacerbations requiring ED visit or hospital admission</p> </li> <li> <p>Post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>AQLQ(S)+12 score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a> </p> <p>(61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group (50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3% sputum eosinophils; and ≥ 2 exacerbations in previous 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 75 (IV) or matched placebo (150 mL of 0.9% saline) at monthly intervals for 1 year </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0019"> <li> <p>Severe exacerbations per person</p> </li> <li> <p>Change in AQLQ</p> </li> <li> <p>Post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Airway hyperresponsiveness</p> </li> <li> <p>Blood/sputum eosinophil counts</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a> </p> <p>(656)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group (24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the last year requiring systemic corticosteroids; FEV<sub>1</sub> &lt; 80%; blood eosinophils ≥ 300 cells/μL or ≥ 150 cells/μL and maintenance OCS or history of nasal polyps or ≥ 2 exacerbations in the last year or FVC &lt; 65% or ≥ 18 years at asthma diagnosis; ACQ‐6 score ≥ 1.5; bronchodilator reversibility ≥ 12% or airway hyperresponsiveness or PEF variability ≥ 10% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐to‐high‐dose ICS + additional controller for ≥ 3 months; ± maintenance OCS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo every 8 weeks (first 3 doses every 4 weeks) for 24 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0020"> <li> <p>Annualised asthma exacerbation rate</p> </li> <li> <p>Change from baseline to week 24 in</p> <ul id="CD010834-list-0021"> <li> <p>SGRQ</p> </li> <li> <p>FEV<sub>1</sub> </p> </li> <li> <p>PEF</p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>PSIA</p> </li> <li> <p>CGI‐C</p> </li> <li> <p>PGI‐C</p> </li> <li> <p>SNOT‐22</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> </p> <p>(290)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT triple‐blind, placebo‐controlled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the previous 12 months; peripheral blood eosinophils ≥ 150 cells/µL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For those aged 6‐11 years, treatment with at least medium‐ to high‐dose ICS</p> <p>For those ≥ 12 years of age, treatment with at least medium‐ to high‐dose ICS in combination with LABA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 40 mg (SC) for 6‐11 year‐olds, 100 mg (SC) for 12‐17 year‐olds every 4 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0022"> <li> <p>Asthma exacerbations treated with systemic corticosteroids</p> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Lung function</p> </li> <li> <p>Quality of life</p> </li> <li> <p>CASI</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> </p> <p>(295)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised, double‐blind, placebo‐controlled, parallel‐group, multicentre study (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had received continuous mepolizumab treatment for ≥ 3 years (initially as part of an RCT, <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>, <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>, or <a href="./references#CD010834-bbs2-0026" title="BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneO , YanceySW , et al. Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study. European Respiratory Journal2014;44 Suppl 58:2907. [CENTRAL: 1053369] BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneON , YanceySW , et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine2014;371(13):1189-97. [CENTRAL: 1013105] [EMBASE: 25199060] [PMID: 25199060]NCT01691508. Mepolizumab steroid-sparing study in subjects with severe refractory asthma [MEA115575: a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma]. clinicaltrials.gov/ct2/show/NCT01691508 (first received 20 September 2012). 4900126000001341 SehmiR , SmithSG , KjarsgaardM , RadfordK , BouletLP , LemiereC , et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clinical and Experimental Allergy2015;46(6):793-802. [CENTRAL: 1129187] [PMID: 26685004]">Bel 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab ≥ 6 months + controller medication ≥ 12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 100 mg (SC) or placebo every 4 weeks for 52 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0023"> <li> <p>Percentage of patients with clinically significant exacerbations (requiring systemic corticosteroids for ≥ 3 days) at 52 weeks </p> </li> <li> <p>Change from baseline in blood eosinophil count</p> </li> <li> <p>Percentage of participants with ≥ 0.5 point increase from baseline in ACQ‐5</p> </li> <li> <p>Percentage of participants with exacerbations requiring hospitalisation or ED visit</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a> </p> <p>(13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, parallel‐group, placebo‐controlled multicentre (48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled asthma taking medium‐dose ICS plus LABA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS (&gt; 250 µg and ≤ 500 µg fluticasone dry powder formulation equivalents total daily dose) and LABA for at least 3 months prior to first visit </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo either every 4 weeks or every 4 weeks for the first 3 doses then every 8 weeks or placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma exacerbations over 48‐week treatment period</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> </p> <p>(576)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, double‐dummy, phase 3 (32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 150 cells/μL at screening or ≥ 300 cells/μL in previous 12 months; and ≥ 2 exacerbations in previous 12 months; and FEV<sub>1</sub> &lt; 80% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS for ≥ 12 months; + additional controller for ≥ 3 months; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 75 mg (IV) or 100 mg (SC) or placebo every 4 weeks for 32 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0024"> <li> <p>Exacerbations per year</p> </li> <li> <p>Mean change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Mean change from baseline SGRQ total score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a> </p> <p>(103)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, placebo‐controlled, dose‐ranging multicentre (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐6 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at least twice during screening; and morning pre‐bronchodilator FEV<sub>1</sub> 40%‐90% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐ to high‐dose ICS in combination with LABA for ≥ 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 2 mg, 20 mg or 100 mg (SC) or placebo every 4 weeks for the first 3 doses, then every 8 weeks (total 7 doses) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0025"> <li> <p>Annual exacerbation rate</p> </li> <li> <p>Lung function</p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>FeNO</p> </li> <li> <p>Blood eosinophil counts</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a> </p> <p>(621)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre, double‐blind, placebo‐controlled (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3% sputum eosinophils or blood eosinophil ≥ 300 cells/μL; and ≥ 2 exacerbations in previous 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS (i.e. ≥ 880 μg/d FP or equivalent daily); + additional controller; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 75 mg, 250 mg or 750 mg (IV) or placebo every 4 weeks for 13 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0026"> <li> <p>Time to first clinically significant exacerbation</p> </li> <li> <p>Frequency of exacerbations requiring hospitalisation</p> </li> <li> <p>Time to first exacerbation requiring hospitalisation or ED visit</p> </li> <li> <p>Mean change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Mean change from baseline post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Mean change from baseline ACQ</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACQ:</b> Asthma Control Questionnaire; <b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>ASUI:</b> Asthma Symptom Utility Index; <b>BDP:</b> beclomethasone dipropionate; <b>CASI:</b> Composite Asthma Severity Index; <b>CGI‐C</b> : Clinician Global Impression of Change; <b>ECP:</b> eosinophil cationic protein; <b>ED:</b> emergency department; <b>FEF<sub>25-75</sub>:</b> forced expiratory flow at 25% to 75% of FVC; <b>FeNO:</b> exhaled fraction of nitric oxide; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>FVC:</b> forced vital capacity; <b>FP:</b> fluticasone propionate; <b>ICS:</b> inhaled corticosteroid; <b>IV:</b> intravenous; <b>LABA:</b> long‐acting beta<sub>2</sub> agonist; <b>OCS:</b> oral corticosteroid; <b>PC<sub>20</sub>:</b> histamine provocative concentration causing a 20% drop in FEV<sub>1</sub>; <b>PEFR:</b> peak expiratory flow rate; <b>PGI‐C:</b> Patient Global Impression of Change; <b>PSIA:</b> Predominant Symptom and Impairment Assessment; <b>RCT:</b> randomised controlled trial; <b>SABA:</b> short‐acting beta<sub>2</sub>‐agonists; <b>SC:</b> subcutaneous; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>SNOT‐22:</b> Sino‐Nasal Outcome Test‐22 </p> </td> </tr> </tbody> </table> </div> <section id="CD010834-sec-0043"> <h5 class="title">Mepolizumab</h5> <p>We included six studies that compared mepolizumab versus placebo, involving a total of 2294 participants distributed as follows: <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> n = 551; <a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a> n = 61; <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> n = 290; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> n = 195; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> n = 576; and <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a> n = 621. </p> <p>Mepolizumab was administered intravenously (IV) in <a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a> (at a dose of 750 mg) and <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a> (at doses of 75 mg, 250 mg and 750 mg), subcutaneously (SC) in <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> and <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> (at a dose of 100 mg) and <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> (at doses of 40 mg for 6 to 11 year‐olds and 100 mg for 12 to 17 year‐olds), and via both routes (75 mg IV or 100 mg SC) in <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> over a range of treatment periods. For <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>, we only included the arm dosed at 75 mg, as this is considered comparable to the 100 mg SC dose that is licensed (according to manufacturer's evidence submission to the UK's National Institute for Health and Care Excellence in November 2015 (<a href="./references#CD010834-bbs2-0354" title="National Institue for Health and Care Excellence, single technology appraisal, mepolizumab for treating severe eosinophilic asthma [ID798]. https://www.nice.org.uk/guidance/ta671/documents/committee-papers-4 (accessed 15 June 2022).">NICE STA</a>)). </p> <p>The studies only included participants with eosinophilic asthma. <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>, <a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>, <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>, and <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a> defined severe disease as requiring high‐dose ICS and a second controller medication plus a history of at least two exacerbations in the preceding 12 months. In addition <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> and <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> required that participants had impaired lung function despite treatment, with an FEV<sub>1</sub> of less than 80%. Eosinophilia was defined as a blood eosinophil count of 150 cells or more per μL at screening or 300 cells or more per μL at some time during the previous year (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>), or either a sputum eosinophil count of 3% or more (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>) and/or a blood eosinophil count of 300 cells or more per μL (<a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>). The blood eosinophil thresholds used in <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> and <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> were identified as those that best predicted response to mepolizumab in a secondary analysis of previous studies (<a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>). <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> used a minimum cut‐off of 150 cells or more per μL for inclusion in the study. <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> recruited severe eosinophilic patients who had earlier been enrolled in <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>, <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> or <a href="./references#CD010834-bbs2-0026" title="BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneO , YanceySW , et al. Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study. European Respiratory Journal2014;44 Suppl 58:2907. [CENTRAL: 1053369] BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneON , YanceySW , et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine2014;371(13):1189-97. [CENTRAL: 1013105] [EMBASE: 25199060] [PMID: 25199060]NCT01691508. Mepolizumab steroid-sparing study in subjects with severe refractory asthma [MEA115575: a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma]. clinicaltrials.gov/ct2/show/NCT01691508 (first received 20 September 2012). 4900126000001341 SehmiR , SmithSG , KjarsgaardM , RadfordK , BouletLP , LemiereC , et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clinical and Experimental Allergy2015;46(6):793-802. [CENTRAL: 1129187] [PMID: 26685004]">Bel 2014</a>, which had the same blood eosinophil and disease severity criteria as <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> but was excluded from the meta‐analysis as the intervention included steroid reduction. The intervention group for <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> continued mepolizumab, while the control group switched to placebo. </p> </section> <section id="CD010834-sec-0044"> <h5 class="title">Reslizumab</h5> <p>We included five studies that compared reslizumab versus placebo, involving a total of 2232 participants distributed as follows: <a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a> n = 468, <a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a> n = 315, <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a> n = 489; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a> n = 464; and <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a> n = 496. Reslizumab was administered subcutaneously in <a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a> at a dose of 110 mg every 4 weeks. Reslizumab was administered intravenously in the remaining four studies over a range of treatment periods at a dose of 3 mg/kg, with an additional arm at a dose of 0.3 mg/kg in <a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>, which we did not include as it is 10 times lower than the licensed dose of 3 mg/kg. </p> <p>All the participants had moderate to severe asthma, defined as requiring medium‐dose ICS. In addition, they had inadequate symptom control, with an ACQ of 1.5 or more. <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a> and <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a> furthermore required a history of at least one exacerbation in the preceding 12 months, and <a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a> required at least two exacerbations during the same time period. Three studies of reslizumab (<a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>), required participants to have a blood eosinophil count of 400 cells or more per μL, which has been shown to be predictive of a sputum eosinophil count of 3% or more in studies of participants with paired blood and sputum samples (<a href="./references#CD010834-bbs2-0323" title="FarooquiN , KhanBQ , WanJY , LiebermanP . Blood eosinophils as markers of inflammation in asthma. Annals of Allergy, Asthma, and Immunology2009;103(5):A56.">Farooqui 2009</a>; <a href="./references#CD010834-bbs2-0364" title="Van VeenIH , Ten BrinkeA , GauwSA , SterkPJ , RabeKF , BelEH . Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. Journal of Allergy and Clinical Immunology2009;124(3):615-7, 617.e1-2. [PMID: 19733302]">Van Veen 2009</a>). <a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a> required a blood eosinophil count of 300 cells or more per μL at screening. <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a> included participants with a range of eosinophil counts. </p> </section> <section id="CD010834-sec-0045"> <h5 class="title">Benralizumab</h5> <p>We included six studies that compared benralizumab versus placebo, involving a total of 3888 participants distributed as follows: <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a> n = 1204; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a> n = 606; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> n = 1306, <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a> n = 656, <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a> n = 13 and <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a> n = 103. All studies administered benralizumab subcutaneously, with dosage varying from 2 mg to 100 mg every four or eight weeks over a range of treatment periods. We only included participants dosed with 20 mg or 30 mg benralizumab in the analysis, as 30 mg is the licensed dose and therefore we considered these the most clinically relevant. <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a> was terminated due to sponsor decision after randomising 13 participants and contributes no data to the review. </p> <p>The severity of asthma among participants varied from moderate to severe, defined as a requirement for maintenance therapy with medium‐ or high‐dose ICS plus LABA. Participants also had poor asthma control, determined by a history of at least two exacerbations in the previous 12 months and an ACQ of 1.5 or above in the studies contributing data. <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a> required a blood eosinophil count of 300 cells or more per μL at screening, but also accepted levels of 150 if other requirements were met. The remaining five studies included participants regardless of eosinophilia, but results were stratified by blood eosinophil count using a threshold of 300 cells or more per μL. </p> </section> </section> <section id="CD010834-sec-0046"> <h4 class="title">Excluded studies</h4> <p>We excluded 287 studies from the review: 115 (40%) because anti‐IL‐5 therapy had not been included in the study; 66 (23%) were an aggregation of studies; 37 (13%) were not randomised placebo‐controlled studies; 21 (7%) had a treatment period of less than 16 weeks; 20 (7%) were conducted on participants without a diagnosis of asthma; 15 (5%) were a post hoc analysis focusing on a specific subgroup (not specified in our protocol); 12 (4%) because the focus was on steroid reduction and 1 study (&lt; 1%) was terminated early because of recruitment issues. (See <a href="./references#CD010834-sec-0128" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010834-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of our risk of bias assessments are available in the <a href="./references#CD010834-sec-0127" title="">Characteristics of included studies</a>, and a summary of our assessment can be seen in <a href="#CD010834-fig-0002">Figure 2</a> and <a href="#CD010834-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010834-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010834-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010834-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010834-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010834-sec-0048"> <h4 class="title">Allocation</h4> <p>We deemed the majority of studies to be at low risk of bias for both random sequence generation and allocation concealment. Three studies (<a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>; <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a>), presented no details on either random sequence generation or allocation concealment and were therefore judged as being unclear risk of bias, whereas a further three (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>), presented no details on allocation concealment so we judged them as unclear risk of bias for that domain (<a href="#CD010834-fig-0003">Figure 3</a>). </p> </section> <section id="CD010834-sec-0049"> <h4 class="title">Blinding</h4> <p>We determined that all studies were at low risk of performance bias, and 11 were at low risk of detection bias; the risk of detection bias was unclear for six studies (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>; <a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a><a href="#CD010834-fig-0003">Figure 3</a>). </p> </section> <section id="CD010834-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>We considered 14 studies to be at low risk of attrition bias, with similar dropout rates in the different study arms ranging from 5% to 20% for the placebo and 2% to 23% for the treatment groups (<a href="#CD010834-fig-0003">Figure 3</a>). We rated one study high risk due to substantial attrition (<a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>). We also deemed <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a> to be high risk because no participants completed the study. There was insufficient information on a further study that has only been published in abstract form thus far, so we judged that study as unclear risk of bias (<a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>). </p> </section> <section id="CD010834-sec-0051"> <h4 class="title">Selective reporting</h4> <p>We considered the risk of reporting bias to be low in 15 studies (<a href="#CD010834-fig-0003">Figure 3</a>), unclear in one study with insufficient data (<a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>), and high in the terminated study (<a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a>). </p> </section> <section id="CD010834-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>We did not note any other potential sources of bias.</p> </section> </section> <section id="CD010834-sec-0053"> <h3 class="title" id="CD010834-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD010834-tbl-0001"><b>Summary of findings 1</b> Mepolizumab subcutaneous (SC) compared to placebo for asthma</a>; <a href="./full#CD010834-tbl-0002"><b>Summary of findings 2</b> Mepolizumab intravenous (IV) compared to placebo for asthma</a>; <a href="./full#CD010834-tbl-0003"><b>Summary of findings 3</b> Reslizumab intravenous (IV) compared to placebo for asthma</a>; <a href="./full#CD010834-tbl-0004"><b>Summary of findings 4</b> Reslizumab subcutaneous (SC) compared to placebo for asthma</a>; <a href="./full#CD010834-tbl-0005"><b>Summary of findings 5</b> Benralizumab subcutaneous (SC) compared to placebo for asthma</a> </p> <section id="CD010834-sec-0054"> <h4 class="title">Mepolizumab (SC) versus placebo</h4> <p>The data for this comparison come from four studies, with a combined total of 1521 participants with severe eosinophilic asthma (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>). Severe eosinophilia was defined as a blood eosinophil count of 300 cells or more per μL in the preceding 12 months or 150 cells or more per μL at screening, historically in the case of <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>, which recruited participants already on mepolizumab from previous studies (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>). <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> used a threshold of 150 eosinophils per μL. Our confidence in the results below is moderate to high, as the studies had a robust methodology. <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> and <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> were large studies, whilst the other two were more modest. <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> (n = 295) had substantial attrition from the blinded study arms (the study assessed cessation versus continuation of long‐term mepolizumab treatment, randomising participants on mepolizumab to placebo or continued mepolizumab; n = 84/151 in the placebo arm and n = 45/144 in the mepolizumab arm were switched to open‐label mepolizumab), but was otherwise methodologically sound. <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> (n = 290) only had conference abstracts and a Clinicaltrials.gov registry entry available at the time of the search. </p> <section id="CD010834-sec-0055"> <h5 class="title">Primary outcomes</h5> <section id="CD010834-sec-0056"> <h6 class="title">Clinically significant asthma exacerbation (as defined by treatment with a course of systemic corticosteroids, with or without hospital attendance or admission) </h6> <p>Mepolizumab SC resulted in a large reduction in clinically significant asthma exacerbations compared to placebo (rate ratio 0.45, 95% CI 0.36 to 0.55; 2 studies, 936 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0004" title="">Analysis 1.1</a>). <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> also examined this outcome but the information published to date does not include participant numbers for each arm and thus we omitted this study from the meta‐analysis. Like the other two studies, <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> found a reduction in clinically significant exacerbations in the intervention group (rate ratio 0.73, 95% CI 0.56 to 0.95). <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> also examined clinically significant exacerbations but used a Cox proportional hazards model to estimate and compare the time to first exacerbation between the intervention and placebo groups. This study found that stopping mepolizumab SC treatment likely resulted in a shorter time to clinically significant exacerbations (hazard ratio 1.61, 95% CI 1.17 to 2.22). </p> </section> </section> <section id="CD010834-sec-0057"> <h5 class="title">Secondary outcomes</h5> <section id="CD010834-sec-0058"> <h6 class="title">Exacerbations requiring emergency department treatment or admission</h6> <p>The rate of exacerbations requiring emergency department treatment or admission from the two studies (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>), that contributed to this outcome was reduced in those receiving mepolizumab SC (rate ratio 0.36, 95% CI 0.20 to 0.66; 2 studies, 936 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0007" title="">Analysis 1.4</a>); and the rate of exacerbations requiring admission in the same two studies was similarly reduced in mepolizumab SC participants versus those receiving placebo (rate ratio 0.31, 95% CI 0.13 to 0.73; 2 studies, 936 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0006" title="">Analysis 1.3</a>). <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> found no evidence for an effect of mepolizumab SC on time to exacerbations requiring emergency department treatment or admission (hazard ratio 1.33, 95% CI 0.50 to 3.54; 295 participants). </p> </section> <section id="CD010834-sec-0059"> <h6 class="title">HRQoL (as measured by a validated questionnaire e.g. ACQ, AQLQ, SGRQ)</h6> <p>Three studies (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>), contributed HRQoL data measured by the ACQ instrument, indicating a moderate effect in favour of mepolizumab SC versus placebo (mean difference (MD) −0.38, 95% CI −0.50 to −0.26; 1231 participants; moderate‐certainty evidence; <a href="./references#CD010834-fig-0008" title="">Analysis 1.5</a>), but this did not meet the minimum clinically important difference (MCID) of 0.5 points in the ACQ. However, mepolizumab SC reduced SGRQ scores by a clinically meaningful improvement in these studies (MD −6.37, 95% CI −8.76 to −3.98; I² = 36%; 3 studies, 1231 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0009" title="">Analysis 1.6</a>); the MCID is −4 points for the SGRQ. </p> <p>The SGRQ is a 50‐item questionnaire with questions covering three domains: symptoms, activity, and impacts (psycho‐social). The ACQ has between five and seven items (there are three variations) focused on asthma symptoms and airflow limitation (the seven‐item ACQ includes short‐acting bronchodilator use for symptom relief and FEV<sub>1</sub>). The intervention may have had broader effects on activity and psycho‐social aspects that were not captured by the ACQ. </p> <p>In a responder analysis, <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> found 59% of participants treated with mepolizumab SC experienced an improvement greater than the MCID of 0.5 points in the ACQ, versus 42% of participants on placebo (P = 0.0014), and 73% had an improvement of greater than the MCID of 4 points in the SGRQ, versus 55% in the placebo arm (P &lt; 0.0001). This is consistent with a post‐hoc responder analysis of the <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> study, where 57% of the mepolizumab SC group achieved an improvement in the ACQ above the MCID compared to 45% of the placebo group (<a href="./references#CD010834-bbs2-0346" title="Llanos-AckertJP , PriceRG , ForshagM , YanceyS , LiuMC . Asthma control in patients with severe eosinophilic asthma treated with mepolizumab. American Journal of Respiratory and Critical Care Medicine2017;195:A3192.">Llanos‐Ackert 2017</a>). </p> <p><a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> reported time to a 0.5‐point increase on the ACQ‐5 instrument, finding that stopping mepolizumab SC likely increased the time to a score increase compared to placebo (hazard ratio 1.52, 95% CI 1.13 to 2.04; 295 participants). </p> </section> <section id="CD010834-sec-0060"> <h6 class="title">Measures of lung function (e.g. FEV<sub>1</sub>) </h6> <p>In a pooled analysis of three studies (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>), there was an increase of 90 mL in pre‐bronchodilator FEV<sub>1</sub> in the mepolizumab SC group (MD 0.09, 95% CI 0.05 to 0.14; 3 studies, 1231 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0010" title="">Analysis 1.7</a>). This is a relatively modest increase; although there is no universally accepted MCID for FEV<sub>1</sub> in asthma; variability within a single testing session can be up to 0.12 L (data from a mixed pool of respiratory participants (<a href="./references#CD010834-bbs2-0322" title="EnrightPL , BeckKC , SherrillDL . Repeatability of spirometry in 18,000 adult patients. American Journal of Respiratory and Critical Care Medicine2004;169(2):235-8. [PMID: 14604836]">Enright 2004</a>)). </p> </section> <section id="CD010834-sec-0061"> <h6 class="title">Serious adverse events</h6> <p>There was some slight evidence for fewer serious adverse events in participants receiving mepolizumab SC when the studies were pooled (risk ratio 0.68, 95% CI 0.46 to 1.01; 3 studies, 1231 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0011" title="">Analysis 1.8</a>). This may be due to a reduction in asthma‐related serious adverse events (e.g. exacerbations requiring hospitalisation, which did decline), with <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> reporting fewer serious adverse events with mepolizumab SC (15/273 (5%) on mepolizumab SC versus 22/278 (8%) on placebo) noting that 12 of these were asthma‐related: three (1%) with mepolizumab SC and nine (3%) with placebo. There were no reports of anaphylaxis after mepolizumab. </p> </section> <section id="CD010834-sec-0062"> <h6 class="title">Clinically significant adverse events (defined as those prompting treatment discontinuation)</h6> <p>There was no evidence for a difference between the two groups with respect to adverse events prompting treatment discontinuation (rate ratio 0.60, 95% CI 0.19 to 1.85; 3 studies, 1231 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD010834-sec-0063"> <h6 class="title">Blood eosinophil counts</h6> <p>Insufficient data were available to analyse this outcome. However, <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> reported a decrease in blood eosinophil counts by week 4, with a maximal drop of 86% by week 12 that was maintained during the study. Those participants who continued mepolizumab SC treatment in the <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> study had consistently lower eosinophil counts than those in the placebo group, a difference that persisted through the entire treatment period (stopping versus continuing mepolizumab: 6.19, 95% CI 4.89 to 7.83). </p> </section> </section> </section> <section id="CD010834-sec-0064"> <h4 class="title">Mepolizumab (IV) versus placebo</h4> <p>The data for this comparison come from three studies (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>), with a combined total of 751 participants, all with severe eosinophilic asthma. There were no subgroups with non‐eosinophilic participants. Our confidence in the results is moderate, as IV delivery is not currently a licenced delivery route for mepolizumab, and although the results for exacerbations mirror those with mepolizumab SC, those for HRQoL measures do not. </p> <section id="CD010834-sec-0065"> <h5 class="title">Primary outcomes</h5> <section id="CD010834-sec-0066"> <h6 class="title">Clinically significant asthma exacerbation (as defined by treatment with a course of systemic corticosteroids, with or without hospital attendance or admission) </h6> <p>All three studies reported the rate of clinically significant exacerbations, which were likely reduced in participants receiving mepolizumab IV compared to placebo (rate ratio 0.53, 95% CI 0.44 to 0.64; 3 studies, 751 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0013" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD010834-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD010834-sec-0068"> <h6 class="title">Exacerbations requiring emergency department treatment or admission</h6> <p>Two studies reported the rate of exacerbations requiring emergency department treatment or admission (<a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>). Mepolizumab IV probably reduces the rate of such exacerbations (rate ratio 0.52, 95% CI 0.31 to 0.87; I² = 5%; 2 studies, 690 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0014" title="">Analysis 2.2</a>). For exacerbations requiring admission, there is little to no evidence for an effect of mepolizumab IV (rate ratio 0.61, 95% CI 0.33 to 1.13; 2 studies, 690 participants; <a href="./references#CD010834-fig-0015" title="">Analysis 2.3</a>). </p> <p>These findings are consistent with results from the third, smaller study (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; 61 participants), which reported three admissions for asthma exacerbations in the mepolizumab IV group (n = 29) compared to 11 in the placebo group (n = 32; P = 0.07), albeit we have low confidence in this finding (risk ratio 0.82, 95% CI 0.61 to 1.09; 61 participants; <a href="./references#CD010834-fig-0016" title="">Analysis 2.4</a>). </p> </section> <section id="CD010834-sec-0069"> <h6 class="title">HRQoL (as measured by a validated questionnaire e.g. ACQ, AQLQ, SGRQ)</h6> <p>Two of the studies (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>), used the AQLQ and ACQ questionnaires, whereas the third used the SGRQ only (<a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>). There is little to no evidence for a difference between mepolizumab IV and placebo for HRQoL when measured using the AQLQ instrument (MD 0.21, 95% CI −0.06 to 0.47; I² = 53%; 2 studies, 369 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0017" title="">Analysis 2.5</a>). Similarly, there is little evidence for a difference between the two groups when measuring HRQoL using the ACQ in these studies (MD −0.11, 95% CI −0.32 to 0.09; 2 studies, 369 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0018" title="">Analysis 2.6</a>). However, mepolizumab IV likely reduces SGRQ scores (MD −6.40, 95% CI −9.65 to −3.15; 1 study, 382 participants; <a href="./references#CD010834-fig-0019" title="">Analysis 2.7</a>). These results conflict with those for mepolizumab SC, but in cases with insufficient evidence to conclude an effect, the trend was in favour of mepolizumab and so it may be that the effect is relatively small and this outcome is therefore underpowered. </p> </section> <section id="CD010834-sec-0070"> <h6 class="title">Measures of lung function (e.g. FEV<sub>1</sub>) </h6> <p>Two studies contributed lung function data (<a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>). Mepolizumab IV slightly increases pre‐bronchodilator FEV<sub>1</sub> (litres) (MD 0.08 L, 95% CI 0.02 to 0.15; 2 studies, 690 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0020" title="">Analysis 2.8</a>). This increase is comparable, but slightly smaller, than that for mepolizumab SC and, at an individual participant level, would be considered within the normal range of variability at a single session (<a href="./references#CD010834-bbs2-0322" title="EnrightPL , BeckKC , SherrillDL . Repeatability of spirometry in 18,000 adult patients. American Journal of Respiratory and Critical Care Medicine2004;169(2):235-8. [PMID: 14604836]">Enright 2004</a>). </p> </section> <section id="CD010834-sec-0071"> <h6 class="title">Serious adverse events</h6> <p>Fewer serious adverse events occurred in the mepolizumab IV group (risk ratio 0.59, 95% CI 0.37 to 0.94; I² = 27%; 3 studies, 751 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0021" title="">Analysis 2.9</a>). As with mepolizumab SC, this may be due to a reduction in asthma‐related serious adverse events but as the individual studies did not report a clear effect, there is no comment by the study authors. </p> </section> <section id="CD010834-sec-0072"> <h6 class="title">Clinically significant adverse events (defined as those prompting treatment discontinuation)</h6> <p>All three studies reported this outcome, finding no evidence for a difference between mepolizumab IV and placebo (risk ratio 0.72, 95% CI 0.18 to 2.92; I² = 24%; 3 studies, 751 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0022" title="">Analysis 2.10</a>). </p> </section> <section id="CD010834-sec-0073"> <h6 class="title">Blood eosinophil counts</h6> <p>Only one small study (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>), reported blood eosinophil counts. Mepolizumab IV likely reduces counts (MD −170.00, 95% CI −230.00 to −110.00; 1 study, 61 participants; <a href="./references#CD010834-fig-0023" title="">Analysis 2.11</a>). <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> also reported a decrease in blood eosinophil counts by week 4, with a maximal drop of 83% by week 12 that was maintained during the study, but did not provide absolute counts that could be included. </p> </section> </section> </section> <section id="CD010834-sec-0074"> <h4 class="title">Reslizumab (IV) versus placebo</h4> <p>The data for this comparison come from four studies (<a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>; <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>), with a combined total of 1652 participants. One of these studies included participants with non‐eosinophilic asthma (<a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>). Our confidence in the results as applied to eosinophilic participants is high, as the studies were large and had a robust methodology. Where data were available for non‐eosinophilic participants, we have compared the effect estimate with that for eosinophilic participants using the test for subgroup difference. </p> <section id="CD010834-sec-0075"> <h5 class="title">Primary outcomes</h5> <section id="CD010834-sec-0076"> <h6 class="title">Clinically significant asthma exacerbation (as defined by treatment with a course of systemic corticosteroids, with or without hospital attendance or admission) </h6> <p>Two studies reported this outcome (<a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>), with the pooled data showing that reslizumab IV reduces clinically significant asthma exacerbations compared to placebo (rate ratio 0.43, 95% CI 0.33 to 0.55; 2 studies, 953 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0024" title="">Analysis 3.1</a>). This analysis only included eosinophilic participants; there were no data for non‐eosinophilic participants. </p> </section> </section> <section id="CD010834-sec-0077"> <h5 class="title">Secondary outcomes</h5> <section id="CD010834-sec-0078"> <h6 class="title">Exacerbations requiring emergency department treatment or admission</h6> <p>The same two studies included data on the exacerbations requiring emergency department treatment or admission, with no evidence for a difference between the treatment groups (rate ratio 0.67, 95% CI 0.39 to 1.17; 2 studies, 953 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0025" title="">Analysis 3.2</a>). Again only eosinophilic participants were included. </p> </section> <section id="CD010834-sec-0079"> <h6 class="title">HRQoL (as measured by a validated questionnaire e.g. ACQ, AQLQ, SGRQ)</h6> <p>Three of the four studies used the AQLQ instrument (<a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>), and all four used ACQ. While reslizumab IV slightly improves HRQoL as measured by AQLQ scores, the MCID of 0.5 points or more is not reached (MD 0.28, 95% CI 0.17 to 0.39; 3 studies, 1164 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0026" title="">Analysis 3.3</a>). This analysis only included eosinophilic participants; there were no data for non‐eosinophilic participants. Similarly, reslizumab IV slightly reduces ACQ scores, though falls short of the MCID of −0.5 points (MD −0.25, 95% CI −0.33 to −0.17; 4 studies, 1652 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0027" title="">Analysis 3.4</a>). Only one study (<a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>), reported data from non‐eosinophilic participants, finding no evidence for a difference between reslizumab IV and placebo. Furthermore, there was no evidence for subgroup differences between eosinophilic and non‐eosinophilic participants (P = 0.19, I² = 41.1%). </p> </section> <section id="CD010834-sec-0080"> <h6 class="title">Measures of lung function (e.g. FEV<sub>1</sub>) </h6> <p>We noted a clear increase in pre‐bronchodilator FEV<sub>1</sub> with reslizumab IV treatment, with data contributed by all four reslizumab IV studies (MD 0.11 L, 95% CI 0.07 to 0.15; I² = 21%; 4 studies, 1652 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0028" title="">Analysis 3.5</a>). The absolute difference of 0.11 L is relatively modest, although there is no consensus around a MCID in FEV<sub>1</sub> in asthma. For this outcome, data from non‐eosinophilic participants were available (again in only one study, <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>), and for that subgroup we observed no evidence for a difference between reslizumab IV versus placebo. The formal test for subgroup differences yielded a P‐value of 0.13 (I² = 56.3%). </p> </section> <section id="CD010834-sec-0081"> <h6 class="title">Serious adverse events</h6> <p>There is little to no effect of reslizumab IV on serious adverse events compared to placebo (risk ratio 0.79, 95% CI 0.56 to 1.12; I<sup>2</sup> = 0%; 4 studies, 1656 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0029" title="">Analysis 3.6</a>). We note that there was also no difference in the rate of hospitalisations due to asthma exacerbations between reslizumab IV and placebo (<a href="./references#CD010834-fig-0025" title="">Analysis 3.2</a>), which would have counted as serious adverse events. This may explain the difference in effect compared to mepolizumab SC. </p> <p>Anaphylaxis was reported in three participants after receiving reslizumab (0.13%). One participant experienced breathlessness, wheezing and flushing shortly after the infusion, but did not have haemodynamic compromise (<a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>). All participants were treated for anaphylaxis with standard management at the study site and tested negative for antibodies to reslizumab. </p> </section> <section id="CD010834-sec-0082"> <h6 class="title">Clinically significant adverse events (defined as those prompting treatment discontinuation)</h6> <p>There was a slight difference between reslizumab IV and placebo for this outcome, which was seen in all the reslizumab IV studies (risk ratio 0.66, 95% CI 0.43 to 1.02; 4 studies, 1659 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0030" title="">Analysis 3.7</a>). </p> </section> <section id="CD010834-sec-0083"> <h6 class="title">Blood eosinophil counts</h6> <p>The blood eosinophil counts were reduced in the reslizumab IV treatment group across all four studies (MD −476.83, 95% CI −499.32 to −454.34; I² = 15%; 4 studies, 1656 participants; <a href="./references#CD010834-fig-0031" title="">Analysis 3.8</a>). This analysis only included eosinophilic participants; note that a reduction in eosinophils amongst participants whose eosinophil counts are within the normal range to start with is not necessarily desirable or achievable. </p> </section> </section> </section> <section id="CD010834-sec-0084"> <h4 class="title">Reslizumab (SC) versus placebo</h4> <p>The data for this comparison come from a single study (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>), which randomised 468 patients. Many of the analyses for this study were stratified by blood eosinophil count, using 300 to less than 400 cells/μL and 400 cells or more per μL as the two analytical groups. However all participants had blood eosinophil counts of 300 or more cells/μL and participants who were truly non‐eosinophilic were excluded. The meta‐analyses for this comparison therefore use all participants. The additional results of the two subgroups (300 to &lt; 400 cells/μL and ≥ 400 cells/μL) are discussed narratively, though we did not conduct a formal test of subgroup differences. </p> <p>A further 177 participants were randomised as part of a second study reported in the same publication, but this study involved oral steroid dose reduction and was therefore excluded from this review. </p> <section id="CD010834-sec-0085"> <h5 class="title">Primary outcomes</h5> <section id="CD010834-sec-0086"> <h6 class="title">Clinically significant asthma exacerbation (as defined by treatment with a course of systemic corticosteroids, with or without hospital attendance or admission) </h6> <p>There was no evidence for a difference in clinically significant asthma exacerbations between reslizumab SC and placebo (rate ratio 0.79, 95% CI 0.56 to 1.11; 464 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0032" title="">Analysis 4.1</a>). In prespecified subgroup analyses, those with a blood eosinophil count of 400 cells or more per μL and treated with reslizumab SC experienced a lower rate of clinical asthma exacerbations (rate ratio 0.64, 95% CI 0.43 to 0.95; 373 participants), with no effect of treatment in a smaller group with more modest blood eosinophilia of 300 to less than 400 cells/μL (rate ratio 1.78, 95% CI 0.69 to 4.58; 90 participants). The threshold blood eosinophil count of 400 cells or more per μL is the same as that used in the studies of reslizumab IV, which did find reductions in clinically significant asthma exacerbations (<a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>; <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>). </p> </section> </section> <section id="CD010834-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD010834-sec-0088"> <h6 class="title">Exacerbations requiring emergency department treatment or admission</h6> <p>There was no difference in the rate of clinical asthma exacerbations requiring emergency department treatment or hospitalisation between the two groups (rate ratio 0.94, 95% CI 0.43 to 2.05; 464 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0033" title="">Analysis 4.2</a>). Subgroup analyses were not reported for this outcome. </p> </section> <section id="CD010834-sec-0089"> <h6 class="title">HRQoL (as measured by a validated questionnaire e.g. ACQ, AQLQ, SGRQ)</h6> <p>There was no observed effect of reslizumab SC on ACQ scores (MD −0.09, 95% CI −0.27 to 0.09; 464 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0035" title="">Analysis 4.4</a>). Subgroup analysis confirmed no effect on either the higher blood eosinophil group with 400 cells or more per μL (MD −0.12, 95% CI −0.32 to 0.08; 373 participants) or the subgroup with 300 to less than 400 eosinophils/μL (MD 0.05, 95% CI −0.38 to 0.48; 90 participants). Similarly, there was no clear benefit of reslizumab SC on AQLQ scores in the overall population (MD 0.08, 95% CI −0.11 to 0.27; 464 participants; high‐certainty evidence) or in the subgroups with blood eosinophil counts of either 400 cells or more per μL (MD 0.08, 95% CI −0.14 to 0.30; 373 participants) or 300 to less than 400 cells/μL (MD 0.05, 95% CI −0.38 to 0.48; 90 participants; <a href="./references#CD010834-fig-0034" title="">Analysis 4.3</a>). Participants on reslizumab SC experienced a slight benefit in SGRQ score at week 32 (MD −3.30, 95% CI −6.02 to −0.58; 464 participants; high‐certainty evidence), but this was below the MCID and did not persist to week 52 (<a href="./references#CD010834-fig-0036" title="">Analysis 4.5</a>). </p> </section> <section id="CD010834-sec-0090"> <h6 class="title">Measures of lung function (e.g. FEV<sub>1</sub>) </h6> <p>Pre‐bronchodilator FEV<sub>1</sub> improved with reslizumab SC versus placebo (MD 0.14, 95% CI 0.06 to 0.22; 464 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0037" title="">Analysis 4.6</a>). The same was seen in the subgroup with a blood eosinophil count 400 cells or more per μL (MD 0.15, 95% CI 0.05 to 0.25; 373 participants), though the 300 to less than 400 cells/μL subgroup had a weaker effect in the same direction (MD 0.13, 95% CI −0.05 to 0.31; 90 participants). The increases were modest for both groups but may have reached a clinically important difference, although this benchmark has not yet been established for FEV<sub>1</sub> in asthma. </p> </section> <section id="CD010834-sec-0091"> <h6 class="title">Serious adverse events</h6> <p>There was no difference in serious adverse events between the groups (risk ratio 0.97, 95% CI 0.53 to 1.79, high‐certainty evidence; <a href="./references#CD010834-fig-0038" title="">Analysis 4.7</a>). </p> </section> <section id="CD010834-sec-0092"> <h6 class="title">Clinically significant adverse events (defined as those prompting treatment discontinuation)</h6> <p>There was no difference in adverse events prompting discontinuation (risk ratio 4.87, 95% CI 0.57 to 41.40; 468 participants; moderate‐certainty evidence; <a href="./references#CD010834-fig-0039" title="">Analysis 4.8</a>). </p> </section> <section id="CD010834-sec-0093"> <h6 class="title">Blood eosinophil counts</h6> <p>Reslizumab SC treatment reduced blood eosinophil counts (MD −0.49, 95% CI −0.58 to −0.40; <a href="./references#CD010834-fig-0040" title="">Analysis 4.9</a>). </p> </section> </section> </section> <section id="CD010834-sec-0094"> <h4 class="title">Benralizumab (SC) versus placebo</h4> <p>The data for this comparison come from five studies (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>), with a combined total of 3304 participants. Four of the five studies included participants with an eosinophilic and non‐eosinophilic phenotype (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>), with more complete data presented for eosinophilic participants. In addition, two studies had additional treatment arms for four‐weekly and eight‐weekly dosing regimens (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>), shown separately in the meta‐analyses with the placebo group split across them (and adjusted accordingly). Our confidence in the results is high, as the studies were large and had a robust methodology. However, limited data were available on non‐eosinophilic subgroups, which were variably consistent with the findings in eosinophilic subgroups. </p> <section id="CD010834-sec-0095"> <h5 class="title">Primary outcomes</h5> <section id="CD010834-sec-0096"> <h6 class="title">Clinically significant asthma exacerbation (as defined by treatment with a course of systemic corticosteroids, with or without hospital attendance or admission) </h6> <p>Benralizumab reduced clinically significant asthma exacerbations in all studies (rate ratio 0.59, 95% CI 0.52 to 0.66; I² = 21%; 4 studies, 3112 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0041" title="">Analysis 5.1</a>). We observed this effect in both eosinophilic and non‐eosinophilic participants, with a stronger effect for the eosinophilic subgroup (eosinophilic: rate ratio 0.55, 95% CI 0.48 to 0.63; 4 studies, 2354 participants; versus non‐eosinophilic: rate ratio 0.69, 95% CI 0.56 to 0.85; 2 studies, 758 participants). However, there was no evidence for a subgroup difference (P = 0.08; I² = 68.4%). </p> </section> </section> <section id="CD010834-sec-0097"> <h5 class="title">Secondary outcomes</h5> <section id="CD010834-sec-0098"> <h6 class="title">Exacerbations requiring emergency department treatment or admission</h6> <p>Two studies (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>), reported exacerbations requiring emergency department treatment or admission, finding that benralizumab likely decreased these exacerbations versus placebo (rate ratio 0.68, 95% CI 0.47 to 0.98; I² = 43%; 2 studies, 1537 participants; moderate‐certainty evidence; <a href="./references#CD010834-fig-0042" title="">Analysis 5.2</a>). This analysis only included eosinophilic participants; there were no data for non‐eosinophilic participants available. However, there was a considerable degree of heterogeneity (I² = 43%), despite <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a> and <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> having the same study design. Both studies noted heterogeneity in the exacerbation history of their participants, <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> specifically commenting that participants recruited in Eastern Europe and South America had fewer exacerbations in the year before study entry than those recruited elsewhere. These would therefore have had less scope for a reduction in exacerbation rate. <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> noted that participants who had had three or more exacerbations in the previous year saw the greatest effects of benralizumab treatment, at rates comparable to <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>. </p> </section> <section id="CD010834-sec-0099"> <h6 class="title">HRQoL (as measured by a validated questionnaire e.g. ACQ, AQLQ, SGRQ)</h6> <p>Three studies included data on AQLQ scores (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>), four on ACQ scores (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>), and one on SGRQ scores (<a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>). AQLQ mean difference was better in the benralizumab group (MD 0.23, 95% CI 0.11 to 0.35; 3 studies, 1541 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0043" title="">Analysis 5.3</a>); for this particular outcome data were available only from eosinophilic participants. However, we observed a similar advantage in favour of benralizumab in combined eosinophilic and non‐eosinophilic participants when measuring HRQoL using the ACQ instrument (MD −0.26, 95% CI −0.34 to −0.17; I² = 37%; 4 studies, 2791 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0044" title="">Analysis 5.4</a>). When analysing the non‐eosinophilic subgroup only, however, the evidence for this effect was weak (MD −0.14, 95% CI −0.30 to 0.02; 2 studies, 755 participants). There was also no strong evidence for subgroup differences (P = 0.09, I² = 64.3%). Neither the AQLQ and ACQ differences reached the MCID of 0.5 points or more. The one study that measured SGRQ scores found a strong improvement with benralizumab versus placebo among eosinophilic participants, exceeding the MCID of 4 points (MD −11.16, 95% CI −15.10 to −7.22; 1 study, 406 participants; <a href="./references#CD010834-fig-0045" title="">Analysis 5.5</a>). </p> <p>One study (<a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>), undertook a responder analysis, which found that 73% and 80% of participants receiving benralizumab experienced an improvement in excess of the MCID in the ACQ and SGRQ respectively, compared to 67% and 68% of participants on placebo (P = 0.019 and P = 0.001 respectively). </p> </section> <section id="CD010834-sec-0100"> <h6 class="title">Measures of lung function (e.g. FEV<sub>1</sub>) </h6> <p>Pre‐bronchodilator FEV<sub>1</sub> was superior in the benralizumab group (MD 0.11, 95% CI 0.08 to 0.15; I² = 35%; 4 studies, 2786 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0046" title="">Analysis 5.6</a>; <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>). However, only eosinophilic participants experienced this benefit: there was strong evidence for a difference between the two subgroups (P = 0.004; I² = 88.2%). The observed improvement of 0.11 L is relatively modest and of a similar magnitude to that seen with the mepolizumab and reslizumab interventions. </p> </section> <section id="CD010834-sec-0101"> <h6 class="title">Serious adverse events</h6> <p>Serious adverse events were reduced in the benralizumab group across the five pooled studies (risk ratio 0.76, 95% CI 0.62 to 0.93; 5 studies, 3304 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0047" title="">Analysis 5.7</a>). Two of the largest studies reported a reduced incidence of serious adverse events with benralizumab (<a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>); the authors noted that the most commonly reported serious adverse event was worsening asthma, as did the authors of the other large study (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>). This was consistent with the effect of the treatment. There were no reports of anaphylaxis after benralizumab. </p> </section> <section id="CD010834-sec-0102"> <h6 class="title">Clinically significant adverse events (defined as those prompting treatment discontinuation)</h6> <p>There were more clinically significant adverse events in the benralizumab group, pooled across all studies except <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>, which did not report this outcome (risk ratio 2.04, 95% CI 1.03 to 4.03; 4 studies, 3253 participants; high‐certainty evidence; <a href="./references#CD010834-fig-0048" title="">Analysis 5.8</a>), based on eosinophilic and non‐eosinophilic participants (including a subgroup of participants whose eosinophil status was not defined). The individual studies did not find evidence for an effect and thus there was no comment by the investigators. However, benralizumab has a different mechanism of action resulting in a larger reduction in eosinophils, which could result in an increase in adverse events. This is an area for further research. </p> </section> <section id="CD010834-sec-0103"> <h6 class="title">Blood eosinophil levels (% change from baseline)</h6> <p>Although four studies included data on blood eosinophil levels, two provided this as a percentage change from baseline (<a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>), whilst the other two provided absolute counts (<a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>). All found marked reductions in blood eosinophil levels with benralizumab. The pooled results of the studies showing this as a percentage change, which includes both eosinophilic and non‐eosinophilic participants, are shown in <a href="./references#CD010834-fig-0049" title="">Analysis 5.9</a> (MD −104.74, 95% CI −116.12 to −93.35; I² = 36%; 2 studies, 2295 participants). In this analysis, there was strong evidence for subgroup differences (P = 0.002; I² = 90%). <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a> reported mean values of 46 to 56 cells per μL in participants with 300 or more cells per μL at baseline, whereas <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a> saw reductions to around 0 cells per μL from a mean of 564 to 824 cells per μL (these data were shown graphically and we could not extract them for inclusion in the meta‐analysis). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010834-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010834-sec-0104"></div> <section id="CD010834-sec-0105"> <h3 class="title" id="CD010834-sec-0105">Summary of main results</h3> <p>Seventeen studies met the inclusion criteria for this systematic review (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>; <a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>; <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>; <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>). Seven studies included adult participants only (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>; <a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a>; <a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a>; <a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a>; <a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a>), one included six to 17 year‐olds only (<a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>), and the remaining nine (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>; <a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a>; <a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a>; <a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a>; <a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a>; <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>), recruited participants aged 12 years and over. Results in adolescents were not reported separately in the latter studies, and thus we could not perform a subgroup analysis on the paediatric population. However the results from the single study in children and adolescents, not yet published in full, are consistent with those in adults (<a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>). </p> <p>The results indicate that treatments targeting IL‐5 or the IL‐5 receptor reduce clinically significant asthma exacerbation rates by approximately half in participants with severe eosinophilic asthma already on standard care with a history of poor control ('clinically significant' exacerbations defined as episodes requiring at least three days' treatment with systemic corticosteroids; standard care defined as at least medium‐dose ICS; poor control defined as either two or more exacerbations in the preceding 12 months or an ACQ score of 1.5 or more). The effect size was comparable across the drugs and formulations, with the exception of reslizumab SC, which was relatively ineffective, although the study design and populations studied differed across studies and no head‐to‐head studies were performed. In addition, treatment with mepolizumab and benralizumab reduced rates of exacerbations requiring emergency department attendance or hospital admission. Non‐eosinophilic participants experienced a smaller reduction in asthma exacerbation rates when treated with benralizumab, but there was no evidence for a subgroup difference. No data were available for mepolizumab or reslizumab treatment in participants with non‐eosinophilic asthma; whether this finding will be replicated with mepolizumab and reslizumab is uncertain, as no studies to assess this are underway. </p> <p>Mepolizumab SC, reslizumab and benralizumab all produced modest improvements in validated HRQoL scores (e.g. ACQ, AQLQ) in severe eosinophilic asthma. However, these did not exceed the MCID for ACQ and AQLQ. The effect size was largest with mepolizumab, although again, the study designs and populations enrolled differed with no head‐to‐head studies to assess this. Improvements in the SGRQ did reach the MCID but came from only four studies, in mepolizumab (<a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>; <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>), and benralizumab (<a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>). This may be due to differences between the questionnaires: the SGRQ is a 50‐item questionnaire with three domains (symptoms, activity, and psychosocial impact); the ACQ is much shorter (five to seven items) and focuses on asthma symptoms and airflow limitation; however the AQLQ is more like the SGRQ, with 32 items in four domains (symptoms, activity, emotional function, environmental stimuli). It is therefore not entirely clear why there were differences between the SGRQ and the AQLQ in particular, although an analysis of the results by question domain might be illuminating in that regard. We found little to no evidence of improvement in ACQ and AQLQ scores in those treated with mepolizumab IV or ACQ scores in non‐eosinophilic participants treated with benralizumab (data were not available for mepolizumab or reslizumab). </p> <p>All anti‐IL‐5 interventions produced an improvement in mean pre‐bronchodilator FEV<sub>1</sub> of between 0.08 L and 0.15 L. There is no agreed definition of a MCID in FEV<sub>1</sub> in asthma, but the reproducibility of FEV<sub>1</sub> values in a single session in participants with a range of respiratory conditions is up to 0.12 L (<a href="./references#CD010834-bbs2-0322" title="EnrightPL , BeckKC , SherrillDL . Repeatability of spirometry in 18,000 adult patients. American Journal of Respiratory and Critical Care Medicine2004;169(2):235-8. [PMID: 14604836]">Enright 2004</a>), suggesting that the increase with anti‐IL‐5 drugs is modest and may not be noticed by participants. </p> <p>Treatment with mepolizumab and reslizumab (both SC and IV) appeared to result in few adverse events, although there remain minor safety concerns over benralizumab. The pooled results of the benralizumab studies showed some evidence for a reduction in severe adverse events. This was most likely due to the reduction in asthma exacerbations requiring hospital admission that would be classed as severe adverse events. However, when considering adverse events prompting participants to discontinue the study drug, whilst mepolizumab and reslizumab treatment were no different to placebo, there were more discontinuations with benralizumab versus placebo, although the absolute numbers were small (42/2026 (2.1%) benralizumab versus 11/1227 (0.9%) placebo). A meta‐analysis of eight benralizumab placebo‐controlled randomised studies in asthma, including those excluded from this review because the treatment duration was less than 16 weeks or the protocol involved oral corticosteroid dose reduction, found that the excess non‐severe adverse events in those treated with benralizumab related to headache and pyrexia, with no excess of hypersensitivity, injection‐site reactions, nasopharyngitis, rhinitis, upper respiratory tract infection, influenza, cough, nausea, back pain or arthralgia (<a href="./references#CD010834-bbs2-0345" title="LiuW , MaX , ZhouW . Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis. Medicine2019;98(22):e15868. [PMID: 31145343]">Liu 2019</a>). This may be due to the different mechanism of action of benralizumab; further research is needed. </p> <p>All anti‐IL‐5 treatments produced marked reductions in blood eosinophil levels. Benralizumab resulted in almost complete depletion of eosinophils from the peripheral circulation, in both eosinophilic and non‐eosinophilic participants, unlike mepolizumab and reslizumab where a few residual eosinophils remained. This is attributed to the ability of benralizumab to induce apoptosis of eosinophils. It is unclear whether this translates into greater clinical efficacy, a greater risk of adverse events, or both. </p> <p>A single study (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>), assessed reslizumab SC, and found it did not reduce clinically significant asthma exacerbations in a population with blood eosinophil counts of 400 cells or more per μL. However, in a prespecified analysis, there was a reduction in exacerbation rates in a subgroup with blood eosinophil counts of 400 cells or more per μL, the same threshold as used in the reslizumab IV studies. Moreover, the study authors noted that the fixed SC dose used, 110 mg, was roughly equivalent to 1 mg/kg reslizumab IV for an average 70 kg man after accounting for bioavailability, compared to the licensed 3 mg/kg reslizumab IV dose. Thus the findings with reslizumab SC do not entirely contradict the results for the other formulations and drugs in this class. </p> <p>Overall the evidence in this review supports the use of anti‐IL‐5 treatments as an adjunct to standard care (at least medium‐dose ICS) in people with severe eosinophilic asthma and a history of poor control (either two or more exacerbations in the preceding 12 months or an ACQ score of 1.5 or more). </p> </section> <section id="CD010834-sec-0106"> <h3 class="title" id="CD010834-sec-0106">Overall completeness and applicability of evidence</h3> <p>A reduction in asthma exacerbations is one of the primary goals of asthma management (<a href="./references#CD010834-bbs2-0325" title="Global Initiative for Asthma (GINA). Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. www.ginasthma.org2021.">GINA 2021</a>). Asthma exacerbations are of major clinical significance as they are the primary cause of morbidity and mortality in asthma, and drive increased healthcare utilisation and cost (<a href="./references#CD010834-bbs2-0371" title="ZeigerRS , SchatzM , DalalAA , QianL , ChenW , NgorEW , et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. Journal of Allergy and Clinical Immunology2016;4(1):120-9.e3. [PMID: 26439182]">Zeiger 2016</a>). This is particularly the case for those with severe asthma, who continue to suffer from frequent exacerbations despite existing treatment options and therefore have a high unmet need (<a href="./references#CD010834-bbs2-0318" title="CustovicA , JohnstonSL , PavordI , GagaM , FabbriL , BelEH , et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy2013;68(12):1520-31. [PMID: 24410781]">Custovic 2013</a>). </p> <p>We found evidence of a reduction in the rate of clinically significant exacerbations in adults with severe eosinophilic asthma with poor control given anti‐IL‐5 treatment, with low heterogeneity between studies. Secondary outcomes included adverse event data showing that anti‐IL‐5 treatments are well tolerated. In addition, the few studies measuring the SGRQ, a broader HRQoL score, found significant improvements with anti‐IL‐5 interventions that exceeded the MCID. Statistically significant but more modest improvements, likely below levels that would be clinically detected by patients, were evident in the narrower AQLQ and ACQ scores, focusing on asthma symptoms, and lung function (FEV<sub>1</sub>). There were also large reductions in blood eosinophil levels but a relationship between these and symptoms is not established and thus this may also be of limited relevance to patients. The evidence on mepolizumab IV and reslizumab SC is of limited applicability as these drugs are not currently available in these formulations. </p> <p>The included studies did not directly compare the different anti‐IL‐5 treatments, however the effect sizes versus placebo were similar. No head‐to‐head studies exist, although indirect treatment comparisons and network meta‐analyses have been published with differing results (<a href="./references#CD010834-bbs2-0311" title="BusseW , ChuppG , NagaseH , AlbersFC , DoyleS , ShenQ , et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. Journal of Allergy and Clinical Immunology2019;143(1):190-200. [PMID: 30205189]">Busse 2019a</a>; <a href="./references#CD010834-bbs2-0314" title="CalzettaL , MateraMG , RoglianiP . Monoclonal antibodies in severe asthma: is it worth it?Expert Opinion on Drug Metabolism and Toxicology2019;15(6):517-20. [PMID: 31104515]">Calzetta 2019</a>; <a href="./references#CD010834-bbs2-0315" title="CasaleTB , PacouM , MesanaL , FargeG , SunSX , CastroM . Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. Journal of Allergy and Clinical Immunology2019;7(1):122-30. [PMID: 30217529]">Casale 2019</a>; <a href="./references#CD010834-bbs2-0320" title="EdrisA , De FeyterS , MaesT , JoosG , LahousseL . Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respiratory Research2019;20(1):179. [PMID: 31395084]">Edris 2019</a>; <a href="./references#CD010834-bbs2-0321" title="EdrisA , LahousseL . Monoclonal antibodies in type 2 asthma: an updated network meta-analysis. Minerva Medica2021;112(5):573-81. [DOI: 10.23736/S0026-4806.21.07623-0]">Edris 2021</a>; <a href="./references#CD010834-bbs2-0327" title="HeLL , ZhangL , JiangL , XuF , FeiDS . Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis. International Immunopharmacology2018;64:223-31. [PMID: 30199847]">He 2018</a>; <a href="./references#CD010834-bbs2-0332" title="IftikharIH , SchimmelM , BenderW , SwensonC , AmrolD . Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung2018;196(5):517-30. [PMID: 30167841]">Iftikhar 2018</a>; <a href="./references#CD010834-bbs2-0359" title="RamonellRP , IftikharIH . Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis. Lung2020;198(1):95-103. [PMID: 31894410]">Ramonell 2020</a>; <a href="./references#CD010834-bbs2-0369" title="YanK , BalijepalliC , SharmaR , BarakatS , SunSX , FalcaoS , et al. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy2019;11(17):1491-505. [PMID: 31686556]">Yan 2019</a>), all limited by the differences in eligibility criteria and outcome measures across the studies. A single study comparing biologicals in asthma, omalizumab versus mepolizumab is ongoing (<a href="./references#CD010834-bbs2-0215" title="NCT03476109. Study of magnitude and prediction of response to omalizumab and mepolizumab in adult severe asthma (PREDICTUMAB) [Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: a pragmatic multicenter trial in Belgium]. clinicaltrials.gov/ct2/show/NCT03476109 (first received 23 March 2018). ">NCT03476109</a>). Pragmatically, reslizumab is given by intravenous infusion necessitating a healthcare setting whereas mepolizumab and benralizumab are given subcutaneously, every four weeks and eight weeks respectively. Thus, there are practical advantages to mepolizumab and particularly benralizumab treatment. </p> <p>Given the mechanism of action of anti‐IL‐5 agents, the studies were predominantly conducted in participants with severe eosinophilic asthma and poor control. It is therefore not possible to draw conclusions about those with milder or better‐controlled disease (e.g. ACQ less than 1.5 with no exacerbations) or non‐eosinophilic asthma. Eosinophilic and severe asthma were variably defined. Most studies considered blood eosinophil counts, although others used sputum eosinophil counts, which are not readily available in most hospitals or clinics (<a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a>; <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>). The thresholds used to determine eosinophilia in blood counts varied, with the mepolizumab studies considering 150 cells or more per μL at screening or 300 cells or more per μL in the previous year (except <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>: 150 cells or more per μL), reslizumab studies using a cut‐off of 400 cells or more per μL (except <a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>'s study of reslizumab SC: 300 cells or more per μL), and benralizumab studies 300 cells or more per μL (except <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>: 150 cells or more per μL). All the included studies defined severe asthma as a requirement to be on stable treatment with at least medium‐dose ICS, but most specified high‐dose ICS, often with additional controller medication(s). In addition, all studies restricted participants to those with uncontrolled asthma. This was either defined in terms of exacerbation history (usually at least two in the previous 12 months; e.g. the studies of mepolizumab), ACQ score (1.5 or more; e.g. the studies of reslizumab), or both (e.g. the studies of benralizumab). Given this heterogeneity, it is unclear exactly how best to select patients for anti‐IL‐5 treatment, although current evidence suggests that a measure of eosinophilia, treatment with at least medium‐dose ICS, and a history of poor control, defined as either two or more exacerbations in the last 12 months or an ACQ score of 1.5 or more, are necessary. </p> <p>None of the included studies extended beyond a year, although several open‐label extension studies have since confirmed that the favourable safety profile of these drugs persists for at least between 1.5 and 3.5 years (<a href="./references#CD010834-bbs2-0308" title="BourdinA , ShawD , Menzies-GowA , FitzGeraldJM , BleeckerER , BusseWW , et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. Journal of Asthma2021;58(4):514-22. [PMID: 31859541]">Bourdin 2021</a>; <a href="./references#CD010834-bbs2-0312" title="BusseWW , BleeckerER , FitzGeraldJM , FergusonGT , BarkerP , SprouleS , et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respiratory Medicine2019;7(1):46-59. [PMID: 30416083]">Busse 2019b</a>; <a href="./references#CD010834-bbs2-0096" title="FitzgeraldJM , BleeckerER , BourdinA , BusseWW , FergusonGT , BrooksL , et al. Two-year integrated efficacy and safety analysis of benralizumab SIROCCO, CALIMA, ZONDA, and BORA trials in severe asthma. American Journal of Respiratory and Critical Care Medicine2019;199(1):A2676. ">Fitzgerald 2019</a>; <a href="./references#CD010834-bbs2-0339" title="KhatriS , MooreW , GibsonPG , LeighR , BourdinA , MasperoJ , et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2019;143(5):1742-51. [PMID: 30359681]">Khatri 2019</a>; <a href="./references#CD010834-bbs2-0340" title="KhuranaS , BrusselleGG , BelEH , FitzGeraldJM , MasoliM , KornS , et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: The COSMEX Study. Clinical Therapeutics2019;41(10):2041-56. [PMID: 31447130]">Khurana 2019</a>; <a href="./references#CD010834-bbs2-0161" title="LugogoN , DomingoC , ChanezP , LeighR , GilsonMJ , PriceRG , et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clinical Therapeutics2016;38(9):2058-2070.e1. [DOI: 10.1016/j.clinthera.2016.07.010]">Lugogo 2016</a>; <a href="./references#CD010834-bbs2-0351" title="MurphyK , JacobsJ , BjermerL , FahrenholzJM , ShalitY , GarinM , et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. Journal of Allergy and Clinical Immunology2017;5:1572-81. [PMID: 29122156]">Murphy 2017</a>). One study assessed the need for ongoing anti‐IL‐5 treatment, comparing cessation to continuation of long‐term mepolizumab (<a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>), finding that the clinical benefits are only sustained if treatment is continued. </p> <p>The potential for anti‐IL‐5 treatments to enable a reduction in maintenance OCS in patients requiring this has been documented in several RCTs (<a href="./references#CD010834-bbs2-0026" title="BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneO , YanceySW , et al. Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study. European Respiratory Journal2014;44 Suppl 58:2907. [CENTRAL: 1053369] BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneON , YanceySW , et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine2014;371(13):1189-97. [CENTRAL: 1013105] [EMBASE: 25199060] [PMID: 25199060]NCT01691508. Mepolizumab steroid-sparing study in subjects with severe refractory asthma [MEA115575: a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma]. clinicaltrials.gov/ct2/show/NCT01691508 (first received 20 September 2012). 4900126000001341 SehmiR , SmithSG , KjarsgaardM , RadfordK , BouletLP , LemiereC , et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clinical and Experimental Allergy2015;46(6):793-802. [CENTRAL: 1129187] [PMID: 26685004]">Bel 2014</a>; <a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>; <a href="./references#CD010834-bbs2-0182" title="AyarsAG , AltmanLC , Potter-PerigoS , RadfordK , WightTN , NairP . Sputum hyaluronan and versican in severe eosinophilic asthma. International Archives of Allergy and Immunology2013;161(1):65-73. 4900100000077338 AyarsAG , AltmanLC , Potter-PerigoS , WightTN , NairP . Sputum hyaluronan as a biomarker of airway remodeling in severe asthma. Journal of Allergy and Clinical Immunology2011;127(2 Suppl 1):AB8. 4900100000027030 NairP , KjarsgaardM , ArmstrongS , EfthimiadisA , O'ByrnePM , HargreaveFE . Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. Journal of Allergy and Clinical Immunology2010;126(2):404-6. [CENTRAL: 759797] [PMID: 20621343]NairP , PizzichiniM , KjarsgaardM , InmanM , EfthimiadisA , PizzichiniE , et al. Prednisone sparing effect of mepolizumab on eosinophilic bronchitis with or without asthma a randomized placebo controlled trial. In: American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A568[#509]. 4900100000023006 NairP , PizzichiniMM , KjarsgaardM , InmanMD , EfthimiadisA , PizzichiniE , et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New England Journal of Medicine2009;360(10):985-93. 4900100000023472 NCT00292877. The prednisone-sparing effect of anti-IL-5 antibody (SB-240563). clinicaltrials.gov/ct2/show/NCT00292877 (first received 15 February 2006). 4900100000020456 ">Nair 2009</a>; <a href="./references#CD010834-bbs2-0184" title="NairP , WenzelS , RabeKF , BourdinA , LugogoNL , KunaP , et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. New England Journal of Medicine2017;376(25):2448-58. ">Nair 2017a</a>). These studies incorporated differing OCS weaning regimens and we therefore considered them too heterogeneous for inclusion in the meta‐analysis, but have nonetheless consistently documented significant OCS‐sparing effects. </p> <p>In summary, anti‐IL‐5 agents represent a new treatment option for severe eosinophilic asthma with poor control, a patient population with a high, unmet need. </p> </section> <section id="CD010834-sec-0107"> <h3 class="title" id="CD010834-sec-0107">Quality of the evidence</h3> <p>Using the GRADE system, we considered the certainty of the evidence for all comparisons to be high overall, except for mepolizumab IV and reslizumab SC, which are not currently licensed delivery routes for these drugs (we therefore regard this as indirect evidence). We are aware of the limitations in some studies and have detailed them in the <a href="./full#CD010834-sec-0039">Results</a>, <a href="#CD010834-fig-0002">Figure 2</a> and <a href="#CD010834-fig-0003">Figure 3</a>. We did not formally assess publication bias through the construction of a funnel plot due to the small number of included studies. However, our search strategy was thorough, including searching conference abstracts and ongoing studies, in order to identify unpublished studies. </p> </section> <section id="CD010834-sec-0108"> <h3 class="title" id="CD010834-sec-0108">Potential biases in the review process</h3> <p>This review and update was based on a published protocol (<a href="./references#CD010834-bbs2-0373" title="PowellC , MilanSJ , DwanK , WaltersN . Mepolizumab versus placebo for asthma. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834]">Powell 2013</a>). We acknowledge the potential for publication bias in this review, as it is possible that we failed to identify unpublished studies that may have provided positive or negative outcomes, which in turn could have altered the treatment benefits. However, to the best of our knowledge, we identified a significant number of studies meeting our inclusion criteria through comprehensive and systematic database searches. We tried to address any study selection bias by having two review authors who independently evaluated all the identified studies. We also ensured that the assessment of each study was consistently in line with the inclusion criteria. </p> </section> <section id="CD010834-sec-0109"> <h3 class="title" id="CD010834-sec-0109">Agreements and disagreements with other studies or reviews</h3> <p>This review is the second update of a previous Cochrane Review, of which the first iteration focused solely on mepolizumab in asthma (<a href="./references#CD010834-bbs2-0374" title="PowellC , MilanSJ , DwanK , BaxL , WaltersN . Mepolizumab versus placebo for asthma. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834.pub2]">Powell 2015</a>, updated in <a href="./references#CD010834-bbs2-0372" title="FarneHA , WilsonA , PowellC , BaxL , MilanSJ . Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834.pub3]">Farne 2017</a>). The previous version noted other reviews with similar findings (<a href="./references#CD010834-bbs2-0313" title="CabonY , MolinariN , MarinG , VachierI , GamezAS , ChanezP , et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clinical and Experimental Allergy2017;47(1):129-38. [PMID: 27859832]">Cabon 2017</a>; <a href="./references#CD010834-bbs2-0342" title="LiJ , WangF , LinC , DuJ , XiaoB , DuC , et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis. Journal of Asthma2017;54(3):300-7. [PMID: 27435534]">Li 2017</a>; <a href="./references#CD010834-bbs2-0344" title="LiuY , ZhangS , LiDW , Jiang S-J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One2013;8(3):e59872. [DOI: 10.1371/journal.pone.0059872]">Liu 2013</a>; <a href="./references#CD010834-bbs2-0366" title="WangFP , LiuT , LanZ , LiSY , MaoH . Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PloS One2016;11(11):e0166833. [PMID: 27875559]">Wang 2016</a>; <a href="./references#CD010834-bbs2-0370" title="YanceySW , OrtegaHG , KeeneON , MayerB , GunsoyNB , BrightlingCE , et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2017;139(4):1167-75.e2. [PMID: 27726946]">Yancey 2017a</a>). Since then, several systematic reviews have assessed anti‐IL‐5 therapies versus placebo for treating asthma. </p> <p> <ol id="CD010834-list-0027"> <li> <p><a href="./references#CD010834-bbs2-0307" title="AgacheI , BeltranJ , AkdisC , AkdisM , Canelo-AybarC , CanonicaGW , et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy2020;75(5):1023-42. [PMID: 32034960]">Agache 2020</a>: a meta‐analysis of benralizumab, mepolizumab, reslizumab and also dupilumab and omalizumab to placebo, including studies incorporating OCS dose reduction </p> </li> <li> <p><a href="./references#CD010834-bbs2-0314" title="CalzettaL , MateraMG , RoglianiP . Monoclonal antibodies in severe asthma: is it worth it?Expert Opinion on Drug Metabolism and Toxicology2019;15(6):517-20. [PMID: 31104515]">Calzetta 2019</a>: a network meta‐analysis that compared mepolizumab, reslizumab and benralizumab (and other biologicals) to placebo, as well as each other </p> </li> <li> <p><a href="./references#CD010834-bbs2-0320" title="EdrisA , De FeyterS , MaesT , JoosG , LahousseL . Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respiratory Research2019;20(1):179. [PMID: 31395084]">Edris 2019</a> a network meta‐analysis that compared mepolizumab, reslizumab and benralizumab (and other biologicals) to placebo, as well as each other </p> </li> <li> <p><a href="./references#CD010834-bbs2-0321" title="EdrisA , LahousseL . Monoclonal antibodies in type 2 asthma: an updated network meta-analysis. Minerva Medica2021;112(5):573-81. [DOI: 10.23736/S0026-4806.21.07623-0]">Edris 2021</a>: a network meta‐analysis that compared mepolizumab, reslizumab and benralizumab (and other biologicals) to placebo, as well as each other </p> </li> <li> <p><a href="./references#CD010834-bbs2-0327" title="HeLL , ZhangL , JiangL , XuF , FeiDS . Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis. International Immunopharmacology2018;64:223-31. [PMID: 30199847]">He 2018</a>: a network meta‐analysis that compared mepolizumab, reslizumab and benralizumab to placebo, as well as each other </p> </li> <li> <p><a href="./references#CD010834-bbs2-0328" title="HenriksenDP , BodtgerU , SideniusK , MaltbaekN , PedersenL , MadsenH , et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. European Clinical Respiratory Journal2018;5(1):1536097. [PMID: 30533206]">Henriksen 2018</a>: a meta‐analysis and indirect comparison of mepolizumab and reslizumab (not benralizumab), including a study incorporating OCS dose reduction </p> </li> <li> <p><a href="./references#CD010834-bbs2-0332" title="IftikharIH , SchimmelM , BenderW , SwensonC , AmrolD . Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung2018;196(5):517-30. [PMID: 30167841]">Iftikhar 2018</a>: a network meta‐analysis that compared mepolizumab, reslizumab and benralizumab (and other biologicals) to placebo, as well as each other </p> </li> <li> <p><a href="./references#CD010834-bbs2-0359" title="RamonellRP , IftikharIH . Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis. Lung2020;198(1):95-103. [PMID: 31894410]">Ramonell 2020</a>: a network meta‐analysis that compared benralizumab, mepolizumab, reslizumab and also dupilumab to placebo, as well as each other </p> </li> </ol> </p> <p>Our findings are consistent with these reviews, despite the inclusion of additional recent studies (<a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a>; <a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a>; <a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a>; <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a>). All the reviews highlight the need for further research in this area, particularly direct head‐to‐head comparisons of the different treatments. </p> <p>Real‐world, observational studies of people with severe asthma receiving anti‐IL‐5 therapies have reported efficacy consistent with, and sometimes superior to, that seen in RCTs and in this review. The largest, an ongoing observational study of more than1800 adults with severe asthma in the USA, reported an annualised exacerbation rate of 0.62 per patient year in those receiving any biologic (including but not only anti‐IL‐5) compared to 0.88 in those on maintenance systemic corticosteroids and 0.91 in those not receiving biologics or maintenance systemic corticosteroids (<a href="./references#CD010834-bbs2-0363" title="TrevorJ , LugogoN , CarrW , MooreWC , SoongW , Panettieri RA Jr, et al. Severe asthma exacerbations in the United States: incidence, characteristics, predictors, and effects of biologic treatments. Annals of Allergy, Asthma and Immunology2021;127(5):579-87. [PMID: 34273485]">Trevor 2021</a>). In the 261 participants who started biologics during the study period, exacerbation rates fell by 43% in those treated with anti‐IgE compared to 62% in those starting another biological (breakdown by treatment not provided but likely to be overwhelmingly anti‐IL‐5/‐IL‐5Rα, rather than the more recently licensed anti‐IL‐4Rα drug dupilumab). Similar findings were reported for emergency department attendances and hospital admissions. Other outcomes (e.g. ACQ, lung function) were not analysed. </p> <p>A systematic review and meta‐analysis of mepolizumab treatment for severe asthma identified 13 studies with 1457 participants and found improvements after 6 to 12 months' treatment in: exacerbations and hospital admissions, quantified in events per patient year; ACQ and ACT scores in excess of the MCID (1.03 and 6.52 points respectively); and 0.23 L in FEV<sub>1</sub> (<a href="./references#CD010834-bbs2-0343" title="LiH , ZhangQ , WangJ , GaoS , LiC , WangJ , et al. Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis. Clinical Therapeutics2021;43(6):192-e208. [PMID: 33962763]">Li 2021</a>). Real‐world reports of benralizumab are similarly consistent with the RCTs (e.g. <a href="./references#CD010834-bbs2-0337" title="KavanaghJE , HearnAP , DhariwalJ , d'AnconaG , DouiriA , RoxasC , et al. Real-2orld 3ffectiveness of benralizumab in severe eosinophilic asthma. Chest2021;159(2):496-506. [PMID: 32882249]">Kavanagh 2021</a>; <a href="./references#CD010834-bbs2-0357" title="PelaiaC , CrimiC , BenfanteA , CaiaffaMF , CalabreseC , CarpagnanoGE , et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. Journal of Asthma and Allergy2021;14:163-73. [PMID: 33654413]">Pelaia 2021</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010834-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD010834-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010834-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010834-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids" data-id="CD010834-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 2: At least one clinically significant exacerbation" data-id="CD010834-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 2: At least one clinically significant exacerbation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 3: Rate of exacerbations requiring admission" data-id="CD010834-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 3: Rate of exacerbations requiring admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 4: Rate of exacerbations requiring ED treatment or admission" data-id="CD010834-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 4: Rate of exacerbations requiring ED treatment or admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 5: Health‐related quality of life (ACQ)" data-id="CD010834-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 5: Health‐related quality of life (ACQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 6: Health‐related quality of life (SGRQ)" data-id="CD010834-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 6: Health‐related quality of life (SGRQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 7: Pre‐bronchodilator FEV 1 (litres)" data-id="CD010834-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 7: Pre‐bronchodilator FEV <sub>1</sub> (litres) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 8: Serious adverse events" data-id="CD010834-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 8: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mepolizumab (SC) versus placebo, Outcome 9: Adverse events leading to discontinuation" data-id="CD010834-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Mepolizumab (SC) versus placebo, Outcome 9: Adverse events leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 1: Rate of clinically significant exacerbations" data-id="CD010834-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 1: Rate of clinically significant exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission" data-id="CD010834-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 3: Rate of exacerbations requiring admission" data-id="CD010834-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 3: Rate of exacerbations requiring admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 4: People with one or more exacerbations" data-id="CD010834-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 4: People with one or more exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 5: Health‐related quality of life (AQLQ)" data-id="CD010834-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 5: Health‐related quality of life (AQLQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 6: Health‐related quality of life (ACQ)" data-id="CD010834-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 6: Health‐related quality of life (ACQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 7: Health‐related quality of life (SGRQ)" data-id="CD010834-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 7: Health‐related quality of life (SGRQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 8: Pre‐bronchodilator FEV 1 (litres)" data-id="CD010834-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 8: Pre‐bronchodilator FEV <sub>1</sub> (litres) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 9: Serious adverse events" data-id="CD010834-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 9: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 10: Adverse events leading to discontinuation" data-id="CD010834-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 10: Adverse events leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mepolizumab (IV) versus placebo, Outcome 11: Blood eosinophil level (cells/μL)" data-id="CD010834-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Mepolizumab (IV) versus placebo, Outcome 11: Blood eosinophil level (cells/μL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids" data-id="CD010834-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission" data-id="CD010834-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 3: Health‐related quality of life (AQLQ)" data-id="CD010834-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 3: Health‐related quality of life (AQLQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 4: Health‐related quality of life (ACQ)" data-id="CD010834-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 4: Health‐related quality of life (ACQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 5: Pre‐bronchodilator FEV 1 (litres)" data-id="CD010834-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 5: Pre‐bronchodilator FEV <sub>1</sub> (litres) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 6: Serious adverse events" data-id="CD010834-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 6: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 7: Adverse events leading to discontinuation" data-id="CD010834-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 7: Adverse events leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Reslizumab (IV) versus placebo, Outcome 8: Blood eosinophil level (cells/μL)" data-id="CD010834-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Reslizumab (IV) versus placebo, Outcome 8: Blood eosinophil level (cells/μL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids" data-id="CD010834-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission" data-id="CD010834-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 3: Health‐related quality of life (AQLQ mean difference)" data-id="CD010834-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 3: Health‐related quality of life (AQLQ mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 4: Health‐related quality of life (ACQ mean difference)" data-id="CD010834-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 4: Health‐related quality of life (ACQ mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 5: Health‐related quality of life (SGRQ mean difference)" data-id="CD010834-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 5: Health‐related quality of life (SGRQ mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 6: Pre‐bronchodilator FEV 1 (litres)" data-id="CD010834-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 6: Pre‐bronchodilator FEV <sub>1</sub> (litres) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 7: Serious adverse events" data-id="CD010834-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 7: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 8: Adverse events leading to discontinuation" data-id="CD010834-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 8: Adverse events leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Reslizumab (SC) versus placebo, Outcome 9: Blood eosinophil level (cells × 10⁹/litre)" data-id="CD010834-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Reslizumab (SC) versus placebo, Outcome 9: Blood eosinophil level (cells × 10⁹/litre) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids" data-id="CD010834-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 1: Rate of exacerbations requiring systemic corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission" data-id="CD010834-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 2: Rate of exacerbations requiring emergency department treatment or admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 3: Health‐related quality of life (AQLQ mean difference)" data-id="CD010834-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 3: Health‐related quality of life (AQLQ mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 4: Health‐related quality of life (ACQ mean difference)" data-id="CD010834-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 4: Health‐related quality of life (ACQ mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 5: Health‐related quality of life (SGRQ mean difference)" data-id="CD010834-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 5: Health‐related quality of life (SGRQ mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 6: Pre‐bronchodilator FEV 1 (litres)" data-id="CD010834-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 6: Pre‐bronchodilator FEV <sub>1</sub> (litres) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 7: Serious adverse events" data-id="CD010834-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 7: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 8: Adverse events leading to discontinuation" data-id="CD010834-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 8: Adverse events leading to discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010834-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/urn:x-wiley:14651858:media:CD010834:CD010834-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Benralizumab (SC) versus placebo, Outcome 9: Blood eosinophil level (% change from baseline)" data-id="CD010834-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_t/tCD010834-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Benralizumab (SC) versus placebo, Outcome 9: Blood eosinophil level (% change from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/media/CDSR/CD010834/image_n/nCD010834-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010834-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mepolizumab subcutaneous (SC) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mepolizumab (SC) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> mepolizumab (SC)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mepolizumab (SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 1.48 events per participant per year<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.81 fewer events per participant per year (95% CI 0.66 fewer to 0.94 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.45 (0.36 to 0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: range 24‐ 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.15 events per patient per year<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.10 fewer events per participant per year (95% CI 0.05 fewer to 0.12 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.36 (0.20 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0‐6 (lower is better)<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −0.4 to −0.5 units<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean in the intervention group was 0.38 units fewer (0.50 fewer to 0.26 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (SGRQ)<br/>Scale from: 0‐100 (lower is better)<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −7.9 to −9.0 units<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 6.4 units fewer (8.9 fewer to 4.0 fewer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 4 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub><br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.086 L (± 0.031 L) to 0.120 L (0.047 to 0.192 L)<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference from placebo was a further 0.09 L (0.05 L to 0.14 L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>65 per 1000 (44 to 96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio 0.68 (0.46 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(3 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.60<br/>(0.19 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1231<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MCID</b> : minimum clinically important difference; <b>SC</b> : subcutaneous; <b>SGRQ</b>: St. George's Respiratory Questionnaire </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rounded mean of the rate in the placebo group of the three studies: 1.21 and 1.74.<br/><sup>b</sup>Rounded mean of the rate in the placebo group of the two studies: 0.10 and 0.20.<br/><sup>c</sup>Mean change in placebo taken from <a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> and <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>. <a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> did not provide the mean change for each group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Mepolizumab subcutaneous (SC) compared to placebo for asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010834-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mepolizumab intravenous (IV) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mepolizumab (IV) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> mepolizumab (IV)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with mepolizumab (IV)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 2.51 events per participant per year<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 1.18 fewer events per participant per year (1.41 fewer to 0.90 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.53<br/>(0.44 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.32 events per participant per year<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.15 fewer events per participant per year (0.22 fewer to 0.04 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.52<br/>(0.31 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>690<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.18 to 0.71 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.21 higher<br/>(−0.06 lower to 0.47 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0‐6 (lower is better)<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −0.59 to −0.50 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.11 lower<br/>(−0.32 lower to 0.09 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: range 32 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.060 L (± 0.038 L) to 0.086 L (± 0.031 L) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.08 L</p> <p>(0.02 L higher to 0.15 L higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>690<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>99 per 1000 (62 to 157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio 0.59 (0.37 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>751<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 32‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(5 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.72<br/>(0.18 to 2.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>751<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV <sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous; <b>MCID</b> : minimum clinically significant difference; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rounded mean of the rate in the placebo group of the three studies: 1.74, 2.40 and 3.4.<br/><sup>b</sup>Rounded mean of the rate in the placebo group of the two studies: 0.20 and 0.43. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mepolizumab intravenous (IV) compared to placebo for asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010834-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Reslizumab intravenous (IV) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Reslizumab (IV) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> reslizumab (IV)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with reslizumab (IV)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 1.54 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.93 fewer events per participant per year (1.09 fewer to 0.73 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.43<br/>(0.33 to 0.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.12 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.04 fewer events per participant per year (0.07 fewer to 0.02 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.67<br/>(0.39 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>953<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.779 to 0.89 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.28 higher<br/>(0.17 higher to 0.39 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1164<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0 to 6 (lower is better)<br/>Follow‐up: range 16 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −0.368 to −0.80 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.25 lower<br/>(−0.33 lower to −0.17 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1652<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.002 L (± 0.1216 L) to 0.215 (± 0.0484 L) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 L higher<br/>(0.07 L higher to 0.15 L higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1652<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/>(51 to 102) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.79<br/>(0.56 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1656<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 16‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(25 to 59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.66<br/>(0.43 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1659<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous <b>MCID</b> : minimum clinically significant difference; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Reslizumab intravenous (IV) compared to placebo for asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010834-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Reslizumab subcutaneous (SC) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Reslizumab (SC) compared with placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> reslizumab (SC) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk for placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with reslizumab (SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.79 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.2 fewer events per participant per year (0.38 fewer to 0.06 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio</p> <p>0.79 (0.56 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.05 events per participant per year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention group was 0.003 fewer events per participant per year (0.03 fewer to 0.05 more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.94 (0.43 to 2.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was 1.06</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>0.08 higher (‐0.11 to 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0 to 6 (lower is better)<br/>Follow up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was ‐1.14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>‐0.09 lower (‐0.27 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (SGRQ)<br/>Scale from: 0 to 100 (lower is better)<br/>Follow up: 32 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was ‐13.1 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.3 lower (‐6.02 to ‐0.58 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 4 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group was 0.23 L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>0.14 higher (0.06 to 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 4 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: 52 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000 (41 to 151)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio</p> <p>0.97 (0.53 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 per 1000 (2 to 166)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio 4.87 (0.57 to 41.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>464 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MCID</b> : minimum clinically important difference; <b>SC</b> : subcutaneous; <b>SGRQ</b>: St. George's Respiratory Questionnaire </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded because of imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Reslizumab subcutaneous (SC) compared to placebo for asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010834-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benralizumab subcutaneous (SC) compared to placebo for asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benralizumab (SC) compared to placebo for asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with asthma<br/><b>Setting:</b> community<br/><b>Intervention:</b> benralizumab (SC)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with benralizumab (SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of clinically significant exacerbations requiring systemic corticosteroids<br/>Follow‐up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 1.2 events per participant per year<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.49 fewer events per participant per year (0.58 fewer to 0.41 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.59<br/>(0.52 to 0.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3112</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of exacerbations requiring emergency department treatment or admission<br/>Follow‐up: range 48‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the placebo group was 0.11 events per participant per year<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rate in the intervention groups was 0.04 fewer events per participant per year (0.06 fewer to 0.002 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.68<br/>(0.47 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is greater heterogeneity (I² = 43%) owing to inclusion of participants with less severe asthma in <a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> (a larger proportion who had only suffered 1 exacerbation the previous year, with correspondingly less potential for exacerbation) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (AQLQ)<br/>Scale from: 1‐7 (higher is better)<br/>Follow‐up: range 48‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from 0.98 to 1.31 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 higher<br/>(0.11 higher to 0.35 higher)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1541<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (ACQ)<br/>Scale from: 0‐6 (lower is better)<br/>Follow up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from −1.19 to −0.76 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.26 lower<br/>(‐0.34 lower to ‐0.17 lower)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2791</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A change of ≥ 0.5 points is considered the MCID</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐bronchodilator FEV<sub>1</sub> (L)<br/>Follow‐up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the placebo group ranged from ‐0.01 L to 0.239 L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.11 L higher<br/>(0.08 L higher to 0.15 L higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2786</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>Follow‐up: range 24‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/>(81 to 121) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio 0.76 (0.62 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3304<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically significant adverse events leading to discontinuation<br/>Follow‐up: range 48‐56 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/>(9 to 36 ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio</p> <p>2.04 (1.03 to 4.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3253<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous; <b>MCID</b> : minimum clinically significant difference; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rounded mean of the rate in the placebo group of the eosinophilic and non‐eosinophilic arms (as applicable) or the three studies: 1.33, 1.21, 0.68, 0.49, 0.93, 1.21.<br/><sup>b</sup>Rounded mean of the rate in the placebo group of the two studies: 0.18 and 0.04.<br/><sup>c</sup>One point deducted to reflect the level of heterogeneity on this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benralizumab subcutaneous (SC) compared to placebo for asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010834-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons of study characteristics</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> <br/><b>(number of participants)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design, follow‐up (weeks)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline asthma severity</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (route)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary and secondary outcomes</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0001" title="BernsteinJA , VirchowJC , MurphyK , MasperoJF , JacobsJ , AdirY , et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine2020;8:461–74. NCT02452190. Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils. clinicaltrials.gov/show/NCT02452190 (first received 13 May 2015). NCT02501629. An efficacy and safety study of reslizumab subcutaneous in patients with oral corticosteroid dependent asthma and elevated blood eosinophils. www.clinicaltrials.gov/ct2/show/NCT02501629 (first received 17 July 2015). ">Bernstein 2020</a> </p> <p>(468)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACQ‐6 score ≥ 1.5; ≥ 2 exacerbations in the last year requiring systemic corticosteroids; blood eosinophils ≥ 300 cells/μL; and FEV<sub>1</sub> bronchodilator reversibility of &lt; 12% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS for ≥ 3 months; + additional controller for ≥ 3 months; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 110 mg (SC) or placebo every 4 weeks for 52 weeks (last dose at 48 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0011"> <li> <p>Clinical asthma exacerbations during 52‐week treatment period</p> </li> <li> <p>Change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Change from baseline in ACQ‐6 at week 52</p> </li> <li> <p>Change from baseline in AQLQ+12 at week 52</p> </li> <li> <p>Change from baseline in SGRQ at week 32</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0002" title="BjermerL , LemiereC , MasperoJ , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. European Respiratory Journal2014;44(Suppl 58):P299. [CENTRAL: 1053372] [EMBASE: 71849984]BjermerL , LemiereC , MasperoJ , WeissS , ZangrilliJ , GerminaroM . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150(4):789-98. [CENTRAL: 1139859] [PMID: 27056586]MasperoJ , BjermerL , LemiereC , CiesielskaM , O'BrienC , ZangrilliJ . A randomized phase 3 study assessing patient reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Annals of Allergy, Asthma and Immunology2014;113(5 Suppl 1):A21. [CENTRAL: 1020022] [EMBASE: 71679175]NCT01270464. A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01270464 (first received 29 December 2010). ">Bjermer 2016</a> </p> <p>(315)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group, fixed‐dosage, multicentre phase 3 (16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 400 cells/μL during 2‐4‐week screening period; and ACQ‐7 score ≥ 1.5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS; maintenance OCS not allowed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 0.3 mg/kg or 3 mg/kg (IV) or placebo every 4 weeks for 4 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0012"> <li> <p>Pre‐bronchodilator FEV<sub>1</sub>, FVC, FEF<sub>25-75</sub> </p> </li> <li> <p>ACQ, ACQ‐6, ACQ‐5</p> </li> <li> <p>ASUI</p> </li> <li> <p>AQLQ</p> </li> <li> <p>Rescue inhaler use</p> </li> <li> <p>Blood eosinophil levels</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0003" title="BleeckerE , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results. European Respiratory Journal2016;48:OA4832. BleeckerER , FitzGeraldJM , ChanezP , PapiA , WeinsteinSF , BarkerP , et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388(10056):2115–27. NCT01928771. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01928771 (first received 16 August 2013). ">Bleecker 2016</a> </p> <p>(1204)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, parallel‐group, placebo‐controlled multicentre (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at enrolment; and FEV<sub>1</sub> &lt; 80% (if 12‐17 years old, &lt; 90%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults (&gt; 18 years) high‐dose (≥ 500 μg/d FP or equivalent) ICS/LABA for ≥ 12 months</p> <p>Children (12‐17 years) at least medium‐dose (≥ 250 μg/day FP or equivalent) ICS/LABA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo either every 4 weeks or every 4 weeks for the first 3 doses then every 8 weeks or placebo for 48 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0013"> <li> <p>Annual exacerbation rate</p> </li> <li> <p>Pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Total asthma symptom score</p> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Annual rate of exacerbations requiring ED visit or hospital admission</p> </li> <li> <p>Post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>AQLQ(S)+12 score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0005" title="BrusselleG , GerminaroM , WeissS , ZangrilliJ . Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulmonary Pharmacology and Therapeutics2017;43:39-45. CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , BardinP , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [DOI: 10.1016/S2213-2600(15)00042-9] [EMBASE: 2015833476]NCT01287039. A study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations in patients (12-75 years of age) with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01287039 (first received 28 January 2011). ">Castro 2015a</a> </p> <p>(489)</p> <p>and</p> <p><a href="./references#CD010834-bbs2-0006" title="CastroM , ZangrilliJ , WechslerME , BatemanED , BrusselleGG , et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(5):355-66. CastroM , ZangrilliJ , WechslerME . Corrections to Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine2015;3(4):e15. [EMBASE: 2015833476]NCT01285323. A study to evaluate the efficacy and safety of reslizumab in patients with eosinophilic asthma. clinicaltrials.gov/ct2/show/NCT01285323 (first received 25 January 2011). ">Castro 2015b</a> </p> <p>(464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 duplicate RCTs, double‐blind, placebo‐controlled, parallel‐group, multicentre, phase 3 (52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 400 cells/μL during 2‐4‐week screening period; and ACQ‐7 score ≥ 1.5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS (i.e. ≥ 440 μg/day FP or equivalent daily); ± additional controller or maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 3 mg/kg (IV) or matching placebo every 4 weeks for 13 doses (last dose week 48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0014"> <li> <p>Annual frequency of exacerbations</p> </li> <li> <p>Change in FEV<sub>1</sub> from baseline over 16 weeks </p> </li> <li> <p>ACQ‐7 score</p> </li> <li> <p>ASUI score</p> </li> <li> <p>Rescue use of SABA</p> </li> <li> <p>Blood eosinophil count</p> </li> <li> <p>‐ AQLQ total score at weeks 16, 32 and 52</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0004" title="CastroM , GossageDL , WardCK , WuY , KhatriDB , MolfinoNA , et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2014;189:B101. [CENTRAL: 1131488] [EMBASE: 72043211]CastroM , WenzelS , KolbeckR , KhatryD , ChristineW , WuY , et al. A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma. European Respiratory Journal2014;44 Suppl 58:2909. [CENTRAL: 1053384] CastroM , WenzelSE , BleeckerER , PizzichiniE , KunaP , BusseWW , et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine2014;2(11):879-9. [PMID: 25306557]EckS , CastroM , SinibaldiD , WhiteW , FolliotK , GossageD , et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma. European Respiratory Journal2014;44 Suppl 58:297. [CENTRAL: 1053403] [EMBASE: 71849982]NCT01238861. Study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma. clinicaltrials.gov/ct2/show/NCT01238861 (first received 9 November 2010). WangB , YanL , HutmacherM , WhiteWI , WardCK , NielsenJ , et al. Exposure-response analysis for determination of benralizumab optimal dosing regimen in adults with asthma. American Journal of Respiratory and Critical Care Medicine2014;189:A1324. [CENTRAL: 1035648] [EMBASE: 72043774]">Castro 2014a</a> </p> <p>(606)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, placebo‐controlled, multicentre dose‐ranging (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐6 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at least twice during screening; and morning pre‐bronchodilator FEV<sub>1</sub> 40%‐90% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐ to high‐dose ICS in combination with LABA for ≥ 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 2 mg, 20 mg or 100 mg (SC) or placebo every 4 weeks for the first 3 doses, then every 8 weeks (total 7 doses) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0015"> <li> <p>Annual exacerbation rate</p> </li> <li> <p>Change from baseline in FEV<sub>1</sub> </p> </li> <li> <p>Mean ACQ‐6 score</p> </li> <li> <p>Overall symptom score</p> </li> <li> <p>Mean AQLQ score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0007" title="ChuppGL , BradfordES , AlbersFC , BrattonDJ , Wang-JairajJ , NelsenLM , et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respiratory Medicine2017;5(5):390-400. NCT02281318. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control. clinicaltrials.gov/show/NCT02281318 (first received 30 October 2014). ">Chupp 2017</a> </p> <p>(551)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled (24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 150 cells/μL at screening or ≥ 300 cells/μL in previous 12 months; and ≥ 2 exacerbations in previous 12 months; and FEV<sub>1</sub> &lt; 80% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS for ≥ 12 months; + additional controller for ≥ 3 months; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 100 mg (SC) or placebo every 4 weeks for 24 weeks (last dose at 20 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0016"> <li> <p>SGRQ</p> </li> <li> <p>Mean change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Proportion of SGRQ total score responders at week 24</p> </li> <li> <p>Mean change from baseline in ACQ‐5</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0008" title="CorrenJ , WeinsteinS , JankaL , O'BrienC , ZangrilliJ . A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal2014;44 Suppl 58:4673. [CENTRAL: 1053393] [EMBASE: 71849958]CorrenJ , WeinsteinS , JankaL , ZangrilliJ , GarinM . Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest2016;150(4):799-810. [CENTRAL: 1139856] [PMID: 27018175]NCT01508936. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma. clinicaltrials.gov/show/NCT01508936 (first received 3 January 2012). ">Corren 2016</a> </p> <p>(496)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, placebo‐controlled, multicentre phase 3 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACQ‐7 score ≥ 1.5 (no selection based on blood eosinophils)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS; maintenance OCS not allowed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reslizumab 3 mg/kg (IV) or matching placebo every 4 weeks for 4 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0017"> <li> <p>Change in FEV<sub>1</sub> from baseline </p> </li> <li> <p>ACQ‐7 score</p> </li> <li> <p>Rescue (SABA) use within previous 3 days</p> </li> <li> <p>FVC</p> </li> <li> <p>Blood eosinophils</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0009" title="FitzGeraldJM , BleeckerE , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab reduces exacerbations in severe, uncontrolled asthma: results of the phase III CALIMA trial [OA1969]. In: European Respiratory Society 26th Annual Congress; 2016 Sep 3-7; London. 2016. FitzGeraldJM , BleeckerER , NairP , KornS , OhtaK , LommatzschM , et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388(10056):2128-41. NCT01914757. A multicentre, randomized, double-blind, parallel group, placebo controlled, phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting beta 2agonist (CALIMA). clinicaltrials.gov/show/NCT01914757 (first received 31 July 2013). ">FitzGerald 2016</a> </p> <p>(1306)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, parallel‐group, placebo‐controlled multicentre (56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at enrolment; and FEV<sub>1</sub> &lt; 80% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐ (≥ 250 μg/d FP or equivalent) to high‐dose (≥ 500 μg/d FP or equivalent) ICS/LABA for ≥ 12 months; high‐dose ICS/LABA for ≥ 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo either every 4 weeks or every 4 weeks for the first 3 doses then every 8 weeks or placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0018"> <li> <p>Annual exacerbation rate for participants with blood eosinophils ≥ 300 cells/μL</p> </li> <li> <p>Pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Total asthma symptom score</p> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Annual rate of exacerbations requiring ED visit or hospital admission</p> </li> <li> <p>Post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>AQLQ(S)+12 score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0010" title="EUCTR2005-001932-61-GB. Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial. clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-001932-61-GB (first received 16 November 2005). GuptaS , HalderP , HargadonB , SousaA , MarshallRP , WardlawAJ , et al. Assessment of changes in airways dimensions with mepolizumab treatment in refractory eosinophilic asthma. In: American Thoracic Society International Conference; 2009 May 15-20 San Diego. 2009:A3641. 4900100000024535 HaldarP , BrightlingC , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab (anti-IL5) and exacerbation frequency in refractory eosinophilic asthma. American Journal of Critical Care and Respiratory Medicine2009;179:A3638. 4900100000024597 HaldarP , BrightlingCE , HargadonB , GuptaS , MonteiroW , SousaA , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine2009;360(10):973-84. 4900100000023473 HaldarP , BrightlingCE , SingapuriA , HargadonB , GuptaS , MonteiroW , et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. Journal of Allergy and Clinical Immunology2014;133(3):921-3. [EMBASE: 2014156329] [PMID: 24418480]ShrimankerR , HargadenB , BraddingP , WardlawAJ , BrightlingCE , GreenR , et al. Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo. European Respiratory Journal2017;50(61):PA3971. ShrimankerR , KeeneO , BrattonDJ , YanceyS , HeaneyL , PavordID . Characterisation of exacerbations of severe eosinophilic asthma on mepolizumab compared to placebo. American Journal of Respiratory and Critical Care Medicine 199;9:A2671. ">Haldar 2009</a> </p> <p>(61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group (50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3% sputum eosinophils; and ≥ 2 exacerbations in previous 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 75 (IV) or matched placebo (150 mL of 0.9% saline) at monthly intervals for 1 year </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0019"> <li> <p>Severe exacerbations per person</p> </li> <li> <p>Change in AQLQ</p> </li> <li> <p>Post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Airway hyperresponsiveness</p> </li> <li> <p>Blood/sputum eosinophil counts</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0011" title="CanonicaGW , HarrisonTW , ChanezP , MenzellaF , LouisR . Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: results from the phase IIIb ANDHI trial. European Journal of Allergy and Clinical Immunology2020;75(109):114. HarrisonTW , ChanezP , MenzellaF , CanonicaGW , LouisR , CosioBG , et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine2021;9(3):260-74. KreindlerJ , ChanezP , BourdinA , BurdenA , GilEG . Comprehensive response to benralizumab by patients with nasal polyposis and severe, eosinophilic asthma. Annals of Allergy, Asthma and Immunology2020;125(5):S29. NCT03170271. A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma (ANDHI) [A multicenter, randomized, double-blind, parallel group, placebo controlled, phase 3b study to evaluate the safety and efficacy of benralizumab 30 mg SC in patients with severe asthma uncontrolled on standard of care treatment]. www.clinicaltrials.gov/ct2/show/NCT03170271 (first received 31 May 2017). ">Harrison 2020</a> </p> <p>(656)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, placebo‐controlled, parallel‐group (24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the last year requiring systemic corticosteroids; FEV<sub>1</sub> &lt; 80%; blood eosinophils ≥ 300 cells/μL or ≥ 150 cells/μL and maintenance OCS or history of nasal polyps or ≥ 2 exacerbations in the last year or FVC &lt; 65% or ≥ 18 years at asthma diagnosis; ACQ‐6 score ≥ 1.5; bronchodilator reversibility ≥ 12% or airway hyperresponsiveness or PEF variability ≥ 10% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐to‐high‐dose ICS + additional controller for ≥ 3 months; ± maintenance OCS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo every 8 weeks (first 3 doses every 4 weeks) for 24 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0020"> <li> <p>Annualised asthma exacerbation rate</p> </li> <li> <p>Change from baseline to week 24 in</p> <ul id="CD010834-list-0021"> <li> <p>SGRQ</p> </li> <li> <p>FEV<sub>1</sub> </p> </li> <li> <p>PEF</p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>PSIA</p> </li> <li> <p>CGI‐C</p> </li> <li> <p>PGI‐C</p> </li> <li> <p>SNOT‐22</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0012" title="AltmanM , BacharierL , VillarrealM , GillM , LiuA , GruchallaR , et al. Distinct airway inflammatory pathways associated with asthma exacerbations are modulated by mepolizumab therapy in children. In: Journal of Allergy and Clinical Immunology. Vol. 149 Suppl 2. 2022:AB146. JacksonD , BacharierL , GergenP , GagalisL , VillarrealM , GillM , et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. Journal of Allergy and Clinical Immunology2022;149(2):AB146. NCT03292588. A trial of mepolizumab adjunctive therapy for the prevention of asthma exacerbations in urban children (MUPPITS-2). https://clinicaltrials.gov/ct2/show/NCT03292588 (first received 29 March 2022). ">Jackson 2022</a> </p> <p>(290)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT triple‐blind, placebo‐controlled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 2 exacerbations in the previous 12 months; peripheral blood eosinophils ≥ 150 cells/µL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For those aged 6‐11 years, treatment with at least medium‐ to high‐dose ICS</p> <p>For those ≥ 12 years of age, treatment with at least medium‐ to high‐dose ICS in combination with LABA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 40 mg (SC) for 6‐11 year‐olds, 100 mg (SC) for 12‐17 year‐olds every 4 weeks </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0022"> <li> <p>Asthma exacerbations treated with systemic corticosteroids</p> </li> <li> <p>Time to first exacerbation</p> </li> <li> <p>Lung function</p> </li> <li> <p>Quality of life</p> </li> <li> <p>CASI</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0013" title="BelEH , MooreWC , KornmannO , PoirierC , KanekoN , SmithSG , et al. Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. European Respiratory Journal2020;56:5280. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Allergy, Asthma &amp; Immunology2020;125(5):S30. LiuM , BelE , KornmannO , HumbertM , KanekoN , MartinN , et al. Clinician/patient perception: asthma severity decreases and response increases with continuing versus stopping long-term mepolizumab (COMET). Annals of Asthma, Allergy and Immunology2020;201:A4211. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized COMET trial. ATS Journals2020;201(1):Meeting Abstracts A421. MooreWC , KornmannO , HumbertM , PoirierC , BelEH , KanekoN , et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal2022;59:2100396. NCT02555371. Cessation versus continuation of long-term mepolizumab in severe eosinophilic asthma patients. clinicaltrials.gov/show/NCT02555371 (first received 17 September 2015). ">Moore 2022</a> </p> <p>(295)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised, double‐blind, placebo‐controlled, parallel‐group, multicentre study (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had received continuous mepolizumab treatment for ≥ 3 years (initially as part of an RCT, <a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a>, <a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a>, or <a href="./references#CD010834-bbs2-0026" title="BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneO , YanceySW , et al. Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study. European Respiratory Journal2014;44 Suppl 58:2907. [CENTRAL: 1053369] BelEH , WenzelSE , ThompsonPJ , PrazmaCM , KeeneON , YanceySW , et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine2014;371(13):1189-97. [CENTRAL: 1013105] [EMBASE: 25199060] [PMID: 25199060]NCT01691508. Mepolizumab steroid-sparing study in subjects with severe refractory asthma [MEA115575: a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab adjunctive therapy to reduce steroid use in subjects with severe refractory asthma]. clinicaltrials.gov/ct2/show/NCT01691508 (first received 20 September 2012). 4900126000001341 SehmiR , SmithSG , KjarsgaardM , RadfordK , BouletLP , LemiereC , et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clinical and Experimental Allergy2015;46(6):793-802. [CENTRAL: 1129187] [PMID: 26685004]">Bel 2014</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab ≥ 6 months + controller medication ≥ 12 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 100 mg (SC) or placebo every 4 weeks for 52 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0023"> <li> <p>Percentage of patients with clinically significant exacerbations (requiring systemic corticosteroids for ≥ 3 days) at 52 weeks </p> </li> <li> <p>Change from baseline in blood eosinophil count</p> </li> <li> <p>Percentage of participants with ≥ 0.5 point increase from baseline in ACQ‐5</p> </li> <li> <p>Percentage of participants with exacerbations requiring hospitalisation or ED visit</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0014" title="NCT01947946. Efficacy and safety study of benralizumab added to medium-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. clinicaltrials.gov/show/NCT01947946 (first received 11 September 2013). ">NCT01947946</a> </p> <p>(13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, parallel‐group, placebo‐controlled multicentre (48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled asthma taking medium‐dose ICS plus LABA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐dose ICS (&gt; 250 µg and ≤ 500 µg fluticasone dry powder formulation equivalents total daily dose) and LABA for at least 3 months prior to first visit </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 30 mg (SC) or placebo either every 4 weeks or every 4 weeks for the first 3 doses then every 8 weeks or placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma exacerbations over 48‐week treatment period</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0015" title="AlbersFC , LugogoN , GilsonMJ , PriceR , YanceySW . Long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology2016;137(2 Suppl 1):AB14. [CENTRAL: 1135293] [EMBASE: 72196801]AlbersFC , PriceR , OrtegaH , YanceySW , NelsenLM . Effect of mepolizumab in severe eosinophilic asthma patients in relation to their baseline ACQ-5 and SGRQ scores. European Journal of Allergy and Clinical Immunology2016;71:257-8. AlbersFC , PriceRG , SmithSG , YanceySW . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Journal of Allergy and Clinical Immunology2017;140(5):1464-6. BasuA , DalalA , CanonicaGW , ForshagM , YanceySW , NagarS , et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research2017;17(2):121-31. ForshagM , DalalAA , OrtegaH , YanceyS , GunsoyNB , CanonicaG . Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2015;191:A4174. [CENTRAL: 1107017] [EMBASE: 72052049]JacksonD , PriceRG , YanceySW , BuhlR , WenzelS . Characterising individual response to mepolizumab treatment. European Respiratory Journal2020;56:S64. MagnanAA , BourdinA , PrazmaCM , AlbersFC , PriceRG , YanceySW , et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. European Journal of Allergy and Clinical Immunology2016;71(9):1335-44. NCT01691521. MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma. clinicaltrials.gov/ct2/show/NCT01691521 (first received 20 September 2012). 4900126000001339 OrtegaH , LiuM , PavordI , BrusselleG , FitzGeraldJM , ChettaA , et al. Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal2014;44 Suppl 58:2906. [CENTRAL: 1053453] OrtegaH , MayerB , YanceyS , KatialR . Response to treatment with mepolizumab in elderly patients. American Journal of Respiratory and Critical Care Medicine2015;191:A4177. [CENTRAL: 1107016] [EMBASE: 72052052]OrtegaHG , LiuMC , PavordID , BrusselleGG , FitzGeraldJM , ChettaA , et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine2014;371(13):1198-207. [EMBASE: 25199059] [PMID: 25199059]OrtegaHG , YanceySW , MayerB , GunsoyNB , KeeneON , BleeckerER , et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine2016;4(7):549–56. [CENTRAL: 1161094] [PMID: 27177493]ShimodaT , OdajimaH , OkamasaA , KawaseM , KomatsubaraM , MayerB , et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergology International2017;66(3):445-51. ">Ortega 2014</a> </p> <p>(576)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, double‐blind, double‐dummy, phase 3 (32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood eosinophils ≥ 150 cells/μL at screening or ≥ 300 cells/μL in previous 12 months; and ≥ 2 exacerbations in previous 12 months; and FEV<sub>1</sub> &lt; 80% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS for ≥ 12 months; + additional controller for ≥ 3 months; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 75 mg (IV) or 100 mg (SC) or placebo every 4 weeks for 32 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0024"> <li> <p>Exacerbations per year</p> </li> <li> <p>Mean change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Mean change from baseline SGRQ total score</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0016" title="AdachiM , Kim M-K, ImaiN , NakanishiT , OhtaK , TohdaY , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. American Journal of Respiratory and Critical Care Medicine2015;191(Meeting Abstracts):A2495. [CENTRAL: 1101040] [EMBASE: 72050330]NCT01412736. A phase IIa study of KHK4563 (4563-003) [A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma]. clinicaltrials.gov/show/NCT01412736 (first received 7 August 2011). ParkHS , KimMK , ImaiN , NakanishiT , AdachiM , OhtaK , et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. International Archives of Allergy and Immunology2016;169(3):135-45. [CENTRAL: 1152856] [EMBASE: 20160326586] [PMID: 27097165]">Park 2016</a> </p> <p>(103)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT double‐blind, placebo‐controlled, dose‐ranging multicentre (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐6 exacerbations in the previous 12 months; and ACQ‐6 score ≥ 1.5 at least twice during screening; and morning pre‐bronchodilator FEV<sub>1</sub> 40%‐90% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐ to high‐dose ICS in combination with LABA for ≥ 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benralizumab 2 mg, 20 mg or 100 mg (SC) or placebo every 4 weeks for the first 3 doses, then every 8 weeks (total 7 doses) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0025"> <li> <p>Annual exacerbation rate</p> </li> <li> <p>Lung function</p> </li> <li> <p>ACQ‐6</p> </li> <li> <p>FeNO</p> </li> <li> <p>Blood eosinophil counts</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010834-bbs2-0017" title="NCT01000506. Dose ranging efficacy and safety with mepolizumab in severe asthma (DREAM) [A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma]. clinicaltrials.gov/ct2/show/NCT01000506 (accessed 16 January 2015). 4900126000001337 OrtegaH , ChuppG , BardinP , BourdinA , GarciaG , HartleyB , et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal2014;44(1):239-41. OrtegaH , LiH , SurukiR , AlbersF , GordonD , YanceyS . Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Annals of the American Thoracic Society2014;11(7):1011-7. [PMID: 24983709]OrtegaHG , ChuppG , BardinP , BourdinA , HartleyB , HumbertM . The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2013;187:A3861. [CENTRAL: 1129378] [EMBASE: 71983360]PavordI , KornS , HowarthP , BleeckerE , BuhlR , KeeneO , et al. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. European Respiratory Journal2012;40 Suppl 56:36s [349]. 4900100000068022 PavordID , KornS , HowarthP , BleeckerER , BuhlR , KeeneON , et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet2012;380(9842):651-9. 4900100000063432 ">Pavord 2012a</a> </p> <p>(621)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre, double‐blind, placebo‐controlled (52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 3% sputum eosinophils or blood eosinophil ≥ 300 cells/μL; and ≥ 2 exacerbations in previous 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose ICS (i.e. ≥ 880 μg/d FP or equivalent daily); + additional controller; ± maintenance OCS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mepolizumab 75 mg, 250 mg or 750 mg (IV) or placebo every 4 weeks for 13 doses</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD010834-list-0026"> <li> <p>Time to first clinically significant exacerbation</p> </li> <li> <p>Frequency of exacerbations requiring hospitalisation</p> </li> <li> <p>Time to first exacerbation requiring hospitalisation or ED visit</p> </li> <li> <p>Mean change from baseline pre‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Mean change from baseline post‐bronchodilator FEV<sub>1</sub> </p> </li> <li> <p>Mean change from baseline ACQ</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>ACQ:</b> Asthma Control Questionnaire; <b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>ASUI:</b> Asthma Symptom Utility Index; <b>BDP:</b> beclomethasone dipropionate; <b>CASI:</b> Composite Asthma Severity Index; <b>CGI‐C</b> : Clinician Global Impression of Change; <b>ECP:</b> eosinophil cationic protein; <b>ED:</b> emergency department; <b>FEF<sub>25-75</sub>:</b> forced expiratory flow at 25% to 75% of FVC; <b>FeNO:</b> exhaled fraction of nitric oxide; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>FVC:</b> forced vital capacity; <b>FP:</b> fluticasone propionate; <b>ICS:</b> inhaled corticosteroid; <b>IV:</b> intravenous; <b>LABA:</b> long‐acting beta<sub>2</sub> agonist; <b>OCS:</b> oral corticosteroid; <b>PC<sub>20</sub>:</b> histamine provocative concentration causing a 20% drop in FEV<sub>1</sub>; <b>PEFR:</b> peak expiratory flow rate; <b>PGI‐C:</b> Patient Global Impression of Change; <b>PSIA:</b> Predominant Symptom and Impairment Assessment; <b>RCT:</b> randomised controlled trial; <b>SABA:</b> short‐acting beta<sub>2</sub>‐agonists; <b>SC:</b> subcutaneous; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>SNOT‐22:</b> Sino‐Nasal Outcome Test‐22 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparisons of study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/full#CD010834-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010834-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mepolizumab (SC) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Rate of exacerbations requiring systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.36, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.36, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 At least one clinically significant exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Rate of exacerbations requiring admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.13, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.13, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Rate of exacerbations requiring ED treatment or admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.20, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.20, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Health‐related quality of life (ACQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.50, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.50, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Health‐related quality of life (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.37 [‐8.76, ‐3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.37 [‐8.76, ‐3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Pre‐bronchodilator FEV <sub>1</sub> (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.05, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.05, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse events leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.19, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.19, 1.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mepolizumab (SC) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010834-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Mepolizumab (IV) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Rate of clinically significant exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Rate of exacerbations requiring emergency department treatment or admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Rate of exacerbations requiring admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.33, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.33, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 People with one or more exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Health‐related quality of life (AQLQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.06, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.06, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Health‐related quality of life (ACQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.32, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.32, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Health‐related quality of life (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Pre‐bronchodilator FEV <sub>1</sub> (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Adverse events leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.18, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.18, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Blood eosinophil level (cells/μL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Mepolizumab (IV) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010834-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Reslizumab (IV) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Rate of exacerbations requiring systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.33, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.33, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Rate of exacerbations requiring emergency department treatment or admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.39, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.39, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Health‐related quality of life (AQLQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.17, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.17, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Health‐related quality of life (ACQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.33, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.36, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.33, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Pre‐bronchodilator FEV <sub>1</sub> (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.08, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.07, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.51, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Eosinophil status unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.34, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Adverse events leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.43, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Eosinophil status unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.35, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Blood eosinophil level (cells/μL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐476.83 [‐499.32, ‐454.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐476.83 [‐499.32, ‐454.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Reslizumab (IV) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010834-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Reslizumab (SC) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Rate of exacerbations requiring systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Rate of exacerbations requiring emergency department treatment or admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Health‐related quality of life (AQLQ mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Health‐related quality of life (ACQ mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Health‐related quality of life (SGRQ mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Pre‐bronchodilator FEV <sub>1</sub> (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Adverse events leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Blood eosinophil level (cells × 10⁹/litre) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Reslizumab (SC) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010834-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Benralizumab (SC) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Rate of exacerbations requiring systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.52, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.48, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Rate of exacerbations requiring emergency department treatment or admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.47, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.47, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Health‐related quality of life (AQLQ mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.11, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.11, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Health‐related quality of life (ACQ mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.34, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.40, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.30, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Health‐related quality of life (SGRQ mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Pre‐bronchodilator FEV <sub>1</sub> (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.08, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.11, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.03, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.62, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.56, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.3 Eosinophil status unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.37, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Adverse events leading to discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.03, 4.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.89, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.54, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.3 Eosinophil status unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.31, 10.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Blood eosinophil level (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐104.74 [‐116.12, ‐93.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐101.74 [‐113.27, ‐90.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 Non‐eosinophilic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐216.81 [‐287.35, ‐146.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Benralizumab (SC) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010834.pub4/references#CD010834-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010834.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010834-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010834-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010834-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010834-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010834-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010834-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010834-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010834\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010834\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010834\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010834\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010834\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010834.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010834.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010834.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010834.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010834.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725160935"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010834.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725160941"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010834.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e74733e001be5',t:'MTc0MDcyNTE2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 